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Tumor-derived nucleic acids (RNA and DNA) may be present in body fluids that had contact 
with malignant or premalignant tissues. Detection of this mutant DNA or aberrant gene 
expression may offer new noninvasive methods for the diagnosis, staging and follow-up of 
patients with cancer. The aim of this thesis was to investigate some promising possibilities of 
molecular tumor-detection in body fluids.
Part I (chapters 2 to 5) deals with the isolation of DNA and subsequent detection of 
mutations (i.e. K-ras oncogene mutations) in various body fluids. Because only minute 
amounts of DNA are present in most body fluids, sensitive and reproducible assays are 
necessary for DNA isolation. A method was developed by use of real-time quantitative PCR 
to compare different DNA isolation methods (chapter 2). Subsequently, DNA was isolated 
from serum, bile, and cerebrospinal fluid from patients with cancers, and tested for the 
presence of mutant K-ras DNA (chapters 3,4 and 5).
Part II (chapters 6 to 9) describes the quantification of gene expression of telomerase 
reverse transcriptase (hTERT), coding for the catalytic subunit of telomerase. First, a method 
was developed for accurate quantification of hTERT mRNA (chapter 6). This technique was 
then applied to several tumors and corresponding normal tissues to identify those tumor types 
that have the best potential to be detected in corresponding body fluids (chapter 7). 
Subsequently, urothelial cell carcinomas were selected for detailed examination of hTERT 
expression (chapter 8). Finally, in chapter 9, the clinical value of hTERT mRNA 
quantification in urine and bladder washings of patients with recurrent urothelial cell 
carcinomas was investigated.
1.1 Outline of this thesis
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1.2 Molecular tumor markers
Current concepts in the molecular biology of cancer emphasize an accumulation of genetic
1 3alterations as a critical element in the emergence of the neoplastic phenotype . The 
mechanism through which these mutations are generated is genetic instability 4-6, although 
also other mechanisms have been proposed 7. In most solid tumors, instability is seen at the 
chromosome level, with frequent gains and losses of whole chromosomes (chromosome 
instability, CIN). In few cases the instability is at the nucleotide level and is the result of 
faulty DNA repair (microsatellite instability). Chromosome translocations and gene 
amplifications add to the chromosomal abnormalities and may reflect additional mechanisms 
for generating instability that occur as tumors progress 6. Instability is the engine of both 
tumor progression and tumor heterogeneity, guaranteeing that no two tumors are exactly alike 
and that no single tumor is composed of genetically identical cells.
The increasing knowledge about the genetic changes that initiate malignant 
transformation, and drive cancer growth and progression, provides a variety of new tumor 
markers. The combination of this knowledge with technological advances, in particular the 
development of the polymerase chain reaction (PCR), offers new methods for detection and 
determination of behaviour of individual tumors, and may ultimately redefine the criteria for 
cancer diagnosis. An overview of genetic changes that may occur during tumor development 
is described.
1.2.1 Malignant transformation
Proto-oncogenes are normal cellular genes that play a role in cell growth, replication or 
differentiation. When activated, the oncogene products impart a positive growth stimulus to 
the cell and, under permissive conditions, this may lead to clonal expansion. Activated
o
oncogenes like ras, myc and erb have been found frequently in a variety of tumors .
The opposite of proto-oncogenes are tumor suppressor genes, which normally exert a 
negative or controlling influence over cell growth. Loss of this regulatory function can 
directly lead to growth advantage. The most frequently altered tumor suppressor gene is p53, 
that controls cellular growth after DNA damage by cell cycle control and apoptosis 9 Other 
tumor suppressor genes mutated in tumors are the APC, p16, and Rb genes.
Genetic alterations in both proto-oncogenes and tumor suppressor genes form the basis 
of malignant transformation. Because these genes code for components in complex 
biochemical pathways, genetic alterations in these genes subsequently cause changes in gene
11
expression of various downstream components of the pathway, such as inappropriately
8
expressed growth factors and constitutively activated growth factor receptors 8.
1.2.2 Immortality
Telomeres are specialized structures at the ends o f eukaryotic chromosomes, consisting o f  
telomere repeats, that appear to function in chromosome protection, positioning and 
replication 10. In normal cells there is a progressive degradation o f telomeres with each cell 
division that will eventually lead to replicative senescence and cell death 11. Telomerase is a 
specialised reverse transcriptase that adds nucleotide repeats to telomeres, counteracting the 
progressive loss o f chromosome ends during replication (Figure 1). The presence of
telomerase activity may indicate the ability to bypass the telomeric “clock” that limits the
12proliferative capacity o f normal somatic cells . Thus, telomerase activity reflects a cell’s
13immortal state . It is therefore not surprising that telomerase is readily present in a great
majority (85%) o f human tumor samples, but not in most healthy tissues 14,15
Figure 1. The function of telomerase
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At the molecular level, at least two components are needed for a functional telomerase 
enzyme: the RNA template, coded by the human telomerase RNA (hTR) gene 16, and the
17human telomerase reverse transcriptase subunit (hTERT gene) , coding for the protein 
component o f the enzyme (Figure 1). The hTERT subunit is the catalytic component, 
meaning that altered expression o f this gene (generally) results in altered telomerase activity
17.
1.2.3 Growth and spread
During the malignant transformation o f cells, genetic changes are also needed for the 
detachment o f tumor cells from the primary tumor mass, invasion into the surrounding 
extracellular matrix, and eventually metastasis to other organs. These genetic events induce 
changes in the expression o f adhesion receptors on the tumor cell surface (e.g. cadherins,
18 19 20CD44) ’ , synthesis o f proteases (e.g. metalloproteinases) , and stimulation o f angiogenesis 
(e.g. VEGF, bFGF)21.
1.3 Tumor detection in body fluids with molecular markers
Body fluid specimens that drain from an organ affected by the tumor can be obtained with 
minimal invasive techniques and are therefore o f great interest for the molecular detection of 
cancer (Table 1). Molecular marker-based tests in body fluids may improve the early 
detection o f cancer and hence the possibilities for curative treatment. Next to early tumor 
detection, molecular diagnosis in body fluids may be helpful in staging o f tumors, in 
determination o f prognosis, in follow-up o f patients, in determination o f response to therapy, 
or as an adjunct to cytology and histology.
In body fluids, nucleic acids originating from the tumor may be present in two forms: 
as whole cells shedded from the tumor mass, or as free molecules. Free molecules are shed 
into the body fluid as a result o f tumor necrosis or apoptosis, or by a mechanism of active
22 23 24release . These “free” nucleic acids are probably complexed to nucleoproteins ’ or 
proteolipids 25,26, because unprotected DNA and RNA are rapidly degraded by DNases and
27 30RNases present in most body fluids - .
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Table 1. M olecular diagnosis o f  tumors in bodyfluids.
Tumor Body fluid Molecular target®
Bladder Urine p53, H-ras, microsatellites, 
telomerase, hTERT mRNA, hTR 
RNA, CD44 mRNA, Cytokeratin 20 
mRNA
Colorectal, Pancreatic, Biliary Stool K-ras, CD44 mRNA
Biliary, Pancreatic Bile, Pancreatic Juice K-ras, p16, telomerase
Leptomeningeal Metastases Cerebrospinal fluid p53, telomerase, gene amplifications
Lung Sputum K-ras, p53, microsatellites, p16 
hypermethylation
Head and Neck Saliva p53
Prostate Ejaculate No reports
All (circulating cells) Blood Many (reviewed in ref. 101)
All (circulating free DNA) Plasma/serum K-ras, p53, microsatellites, p16 
hypermethylation (reviewed in ref. 22)
a Markers reported in literature
The amounts of tumor DNA or RNA in body fluids are usually very small, below the 
detection limit of conventional detection techniques such as blot hybridization. Together with 
the development of sensitive DNA and RNA isolation methods, the invention of the PCR, not
31 32more than a decade ago ’ , has allowed amplification of these low quantities of DNA of 
interest. In this enzymatic reaction, target molecules can be amplified over a billionfold to 
yield quantities of DNA amenable for analysis. PCR amplification can also be accomplished 
using RNA as starting material. This procedure, known as reverse transcriptase PCR (RT- 
PCR) is similar to DNA-PCR with the modification that PCR amplification is preceded by 
reverse transcription of RNA into complementary DNA (cDNA).
In the following paragraphs, the rapidly evolving field of amplification and detection 
of molecular tumor markers in body fluids is described.
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1.3.1 Urine
The value of mutations as molecular markers for cancer diagnosis in body fluids was first 
demonstrated for bladder cancer; p53 mutations were found in the urine of 3 patients with
33 34 35bladder cancer . These original findings were confirmed by other studies . Although p53 
mutations occured in half of the muscle invasive bladder tumors, they were present in only 
10% of the superficial tumors 36,37 This indicated an interesting application as a prognostic 
marker, but limited use for early detection because most primary tumors are superficial at
38clinical presentation. Moreover, p53 mutations can occur over a wide region of the gene , 
which makes mutation analysis laborious.
In contrast to the p53 tumor suppressor gene, mutations of the H-ras oncogene are 
concentrated at 3 hot-spots (codons 12, 13, and 61), hence more easy to detect. H-ras 
mutations have been detected in urine 39,40 ,but do not represent a frequent molecular change 
in bladder cancers.
Telomerase activity, however, is present in 95% of the bladder tumors, regardless of 
stage and grade 41,42 This suggests the presence of telomerase from the early stages of 
carcinogenesis, and its potential use for early diagnosis. Telomerase activity was found in 
urine samples of patients with primary bladder cancer 43-45.
Other potential markers for early detection are microsatellite markers. In recent 
studies, a combination of several microsatellite loci could detect either loss of heterozygosity 
or microsatellite shifts in up to 95% of the urine samples of patients with various grades and 
stages of bladder carcinomas 46-49
Aberrant mRNA expression from exfoliated tumor cells in the urine has been found 
using RT-PCR for a variety of genes coding for: both subunits of telomerase (hTERT and 
hTR)50,51, cell surface adhesion molecules (CD44)52,53, epithelial cell cytoskeleton 
(cytokeratin 20)54,55, and hormones (hCG)56. For most mRNA markers, sensitivity for the 
detection of bladder tumors in urine was high (>80%), except for hCG (43%)56. Specificity 
varied significantly; from 69% for cytokeratin 20 mRNA 54 to 96% for hTERT mRNA
50expression .
1.3.2 Stool
In 1992, Sidransky and collegues were able to detect K-ras oncogene mutations in the stool of
578 of 9 patients, which contained mutated K-ras in their colorectal tumors . Also in other 
studies, mutant K-ras could be detected in stool samples of patients with colorectal and 
pancreatic tumors, but with highly variable sensitivities 58-60. One of the main obstacles for
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mutation analysis in feces is the complexity to isolate high quality human DNA without PCR 
inhibitors. These inhibitors may consist of miscellaneous chemical substances, such as bile 
salts 61, but also the presence of large amounts of bacterial DNA could inhibit the PCR. 
Inhibition may be handled by dilution, however, the mutant template can be diluted beyond 
the amplifiable level. Moreover, in order to avoid false-negative results due to sampling error 
62, a relative large sample is needed, thus making it more difficult to remove all PCR 
inhibitors.
Another obstacle is the high background of non-mutant K-ras gene DNA derived from 
normal colonic cells shedded in the feces. Highly sensitive PCR-based methods for mutation 
detection are therefore required.
All of these problems resulted in the need of laborious and cumbersome DNA 
isolation and mutation detection methods 59,63,64, increasing the risk of contamination of stool 
samples with previously amplified PCR products.
Finally, although the occurance of a K-ras mutation is an early event in colorectal 
carcinogenesis 3, it is only present in a maximum of 50% of all colorectal tumors 65,66. Once 
reliable methodologies are established, other genetic targets, such as APC, P-catenin and 
CD44 could be adopted jointly to improve the sensitivity of clinical screening in stool for
DNA from colorectal cancer 67,68.
1.3.3 Bile and Pancreatic Juice
In pancreatic carcinogenesis, K-ras oncogene mutations are involved in 95% of the cases 69,70. 
Also in corresponding clinical samples, such as bile and pancreatic juice, K-ras mutations 
were frequently found 71-76. These body fluids can be collected by cannulation of the bile duct, 
the pancreatic duct, or by secretin stimulation of the pancreas and collection of pancreatic 
secretion in the duodenum. However, K-ras mutations were found in patients with non-
77-80neoplastic pancreatic diseases . The significance of these latter findings for testing of 
clinical samples remains unknown. Possibly, K-ras mutations are not specific for malignancy,
and the presence of a K-ras mutation alone in a clinical sample is no proof for the presence or
81imminent development of cancer . Other mutated genes, which can be combined with K-ras 
mutation analysis in bile and pancreatic juice, are the tumor suppressor genes p53 and p16, 
although mutations in these genes are not as frequent as K-ras mutations and more difficult to 
detect 82-84
85Telomerase activity has been detected in 95% of pancreatic carcinomas . It was also 
present in a minority of samples from chronic pancreatitis and healthy tissues, but always
16
85 86 87with lower activity than the tumors ’ . Identical results were found for pancreatic juice . 
Typically, in one study where the presence of K-ras mutations and telomerase activity were 
compared in pancreatic juice, telomerase activity was detected (above threshold level) in 80%
of the subjects with pancreatic cancer, but in none of the patients with chronic pancreatitis or
88normal pancreas . The frequency of K-ras mutations in these tumors was equal to the
presence of telomerase, but less specific because patients with chronic pancreatitis or normal
88tissue also contained mutated K-ras .
Like pancreatic tumors, K-ras mutations occur frequently in bile duct tumors and gall 
bladder cancer 89,90, and were subsequently detected in bile 76,91. The predictive value of K-ras 
mutations for the presence or progression to biliary cancer is still unknown, since K-ras 
mutations were also found in dysplastic epithelia of the gall bladder 90.
1.3.4 Cerebrospinalfluid
In one patient with glioblastoma, a p53 mutation was detected in both tumor and
92cerebrospinal fluid . In another study, gene amplifications were detected in the cell-free 
fraction of the cerebrospinal fluid of 2 patients with metastatic breast carcinoma and
93glioblastoma, respectively . Also telomerase activity could be detected in cerebrospinal fluid 
94 These studies suggested that molecular analysis of cerebrospinal fluid may identify 
patients with (recurrent) intercranial tumors or metastatic disease.
1.3.5Sputum, saliva, ejaculate
Both K-ras mutations 95,96, p53 mutations 95, microsatellite instability 97, and p l6  hyper-
98methylation have been succesfully detected in sputum of patients with lung cancer. Only 
few results were reported on the molecular detection of head and neck cancer in saliva 99, or 
prostate cancer cells in ejaculate 100.
1.3.6Blood
Many reports have been published about the detection of circulating tumor cells in whole 
blood. However, this is beyond the scope of this introduction. A comprehensive review on 
this subject was recently published by Ghossein et al.101.
1.3.7 Plasma/serum
The clinical significance of free circulating DNA in serum was first appreciated in patients
102with systemic lupus erythematosus . In cancer patients, high levels of circulating DNA
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were detected especially in patients with systemic disease, while patients with inflammatory 
diseases and healthy subjects had lower levels 103-105. Circulating DNA in cancer patients was 
found to be double-stranded with neoplastic characteristics 106,107 The development o f simple 
DNA extraction and amplification methods allowed the first molecular detection o f mutated 
oncogenes in the plasma o f patients with haematological malignancies and pancreatic 
carcinoma 108,109 These initial molecular studies were confirmed by other studies in plasma 
and serum of patients with lung cancer and head and neck cancer using mirosatellite markers
110,111. Typically, patients with microsatellite alterations in plasma had larger tumors and
112worse prognosis than patients without microsatellite alterations . Also in patients with 
pancreatic carcinoma, presence o f a K-ras mutation in the plasma correlated with large tumor
113size and these patients were less likely to have a curative resection . Studies in patients with 
colorectal carcinoma showed high positivity rates for mutant K-ras in plasma or serum of 
patients with metastatic disease 114,115, but much lower sensitivities in patients without 
systemic disease 116. For details, a comprehensive literature overview was recently published 
by Anker et al.22.
1.4 Detection of tumor DNA in body fluids
Genetic alterations in oncogenes or tumor suppressor genes may exist o f various changes, 
such as mutations, deletions, insertions, translocations, amplifications, or transcriptional 
silencing by promoter methylation. The type o f DNA alteration determines the detection 
strategy and in this regard numerous methods have been developed. In body fluids, mutations 
were most frequently studied, however with variable success. Therefore, this paragraph will 
concentrate on the limitations and drawbacks o f the detection o f mutated tumor DNA in body 
fluids.
As mentioned previously, the amounts o f mutated DNA in body fluids are often very 
small and require amplification before analysis. Amplification is driven by an enzymatic 
reaction and strict physiological conditions are required. The presence o f inhibitors in the 
reaction will influence the efficiency of the enzymatic reaction during each PCR cycle. For 
instance, red blood cells, frequently present in body fluids, contain a powerful PCR inhibitor
117. Especially when many PCR cycles are necessary to detect small amounts o f target DNA, 
inhibitors may have a high impact on sensitivity, even when low in concentration. Therefore, 
DNA isolation methods are required that are able to eliminate (all) PCR inhibitors from body 
fluids before PCR amplification. The most complex body fluid is feces, from which total
18
elimination of the many inhibitors will be practically impossible. As a result, most studies in 
feces were forced to use additional, mostly cumbersome methods to improve sensitivity. 
Comparison of various (commercial) DNA isolation methods is necessary to select the most 
sensitive and reproducible method for each body fluid.
After the isolation of DNA from a particular body fluid, mutated DNA from the tumor 
will be present in the sample together with DNA from shedded normal cells. Typically, in 
urine and saliva specimen, the percentage of mutant DNA compared to normal DNA was 
found to be in the range of 1% to 5% 99 This percentage is even lower in sputum and fecal 
samples 95. Because the proportion of tumor cells to normal cells varies considerably from 
one organ system to another and from one individual to another, very sensitive PCR-based
approaches for mutation detection are necessary for (early) tumor detection. Methods have
118been developed, such as mutant enriched PCR and mutant allele specific amplification
58(MASA) , that can detect 1 mutant gene in a background of 10,000 normal gene copies. A 
prerequisite for these methods is that mutations are localized. This implies that ras mutations 
(localized to codons 12 and 13) can be detected, whereas for example p53 and APC 
mutations, that occur over a wide region of the gene, can not be detected with these sensitive 
methods without prior knowledge of the exact mutation. Most identified oncogenes and tumor 
suppressor genes do not have localized mutations, and therefore studies have primarily 
focussed on the detection of ras mutations. This increase in sensitivity of point-mutation 
detection methods compromised specificity to some extent, illustrated by a study of Smith- 
Ravin et al.119, who detected K-ras mutations in the stool of 3 of 8 patients with colorectal
carcinomas different from mutations identified in the primary tumor. Specificity seems to be
120 121highly dependent on PCR amplification conditions , . Therefore, repeated experiments 
and careful control of PCR conditions are necessary to reduce false positives.
1.5 Quantification of tum or RNA in body fluids
Genetic alterations of oncogenes and tumor suppressor genes disturb the balance of complex 
biochemical pathways. This disruption may result in vast changes in the RNA expression of 
various genes and can be used as indirect tumor markers. Measurement of gene expression 
may be more sensitive than DNA mutation analysis because genes (when activated) express 
multiple RNA copies per cell, whereas only one mutant DNA copy is usually present. 
However, RNA is more prone to degradation in body fluids. Also careful isolation methods 
are necessary.
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Gene expression differences between normal and tumor cells can be examined with 
various techniques, including Northern blotting analysis, RNase protection assay, and 
quantitative RT-PCR. Northern blotting is an essential procedure for transcript analysis, since 
it is the only technique that can determine both size and amount of a specific mRNA. 
However, its sensitivity is relatively low and large amounts of starting material are required 
for detection of low abundance mRNA. RNase protection assay, on the other hand, is about 
10 times more sensitive, but a less straightforward technique for mRNA quantification. It is 
still not sensitive enough to detect low abundance mRNA and the procedure is time­
consuming to establish and optimize for each target mRNA. The polymerase chain reaction is 
much more sensitive than both other methods and can be made highly specific. Because most 
body fluids contain only small numbers of tumor cells, quantitative RT-PCR is the best option 
for determining aberrant gene expression.
Several processes for quantitative (RT-) PCR have been proposed, like accurate
122 123measurements of PCR products , , or strategies involving coamplification of an external
124reference gene as normalization (differential PCR) . However, with these techniques it is 
extremely laborious to ensure that all samples are analysed during the exponential phase of 
the PCR reaction for both target gene and normalization gene. The development of
125competitive PCR using an internal standard has made quantitation easier; it is not essential 
to analyse PCR products during the exponential phase of the reaction. Unfortunately, design 
of the competitor and the validation of amplification efficiencies requires a dedicated effort 
and quantification is manual, thus subjective. Moreover, all methods have time-consuming 
postamplification steps for the measurement of nucleic acid target (DNA or mRNA) that 
introduce variables and increase risk of carryover contamination.
Recently, a novel quantitative method was developed: real-time quantitative PCR 
126,127 The system has a closed tube amplification and detection format, reducing time of 
analysis and contamination risk. Detection is standardized by the use of a computer which 
eliminates inter- and intra-observer variability. Quantification of input target is automatically 
performed in the exponential phase of the PCR reaction.
Since the introduction of real-time quantitative PCR with TaqMan™ technology
126,127, several other methods have been described for real-time monitoring of PCR product
128formation, such as the use of molecular beacons . In this thesis only TaqMan™ technology 
was used for quantification and this principle will be explained in the successive paragraphs.
TaqMan™ technology exploits the 5’ nuclease activity of some Taq polymerases to 
cleave a fluorescent probe during PCR. The probe contains a reporter dye at the 5’ end and a
20
quencher dye at the 3’ end. When the probe is intact, the proximity of the reporter dye to the 
quencher dye results in suppression of the reporter fluorescence primerily by Forster-type
129energy transfer 129. Every PCR cycle, when target is present, the probe specifically anneals 
between the forward and reverse primer sites. During the reaction, nuclease cleavage of the 
probe separates the reporter dye and the quencher dye, which results in increased fluorescence 
of the reporter. Accumulation of PCR products is therefore detected directly by monitoring 
the increase in fluorescence of the reporter during every PCR cycle (real-time). In the reaction 
mixture a passive reference dye is included (6-carboxy-X-rhodamine, ROX) which does not 
participate in the 5’ nuclease assay. The passive reference provides an internal reference to 
which the reporter-dye signal can be normalized during data analysis. Normalization is
130necessary to correct for fluorescent fluctuations due to changes in concentration or volume 130. 
Normalization is accomplished by dividing the emission intensity of the reporter dye by the 
emission intensity of the passive reference to obtain a ratio defined as the Rn (normalized 
reporter) for a given reaction tube. The ARn is the difference in Rn between the signal of a 
PCR tube without template (no template control) and a PCR tube with template (sample, 
Figure 2). The threshold cycle or Ct-value is the PCR cycle at which a statistically significant 
increase in ARn is first detected. Threshold is defined as the average standard deviation of Rn 
for the early cycles (normally PCR cycles 3 to 15), multiplied by an adjustable factor 
(normally x10) . As can be seen in figure 2, the cycle threshold occurs when the system (ABI 
Prism™ 7700 Sequence Detection System, Perkin-Elmer Biosystems) begins to detect the 
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Figure 2. Arnplificationplots for no template control and apositive sample with 
determination of cycle threshold (Ct) value (adaptedfrom ref 130).
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The Ct-values of all samples are proportional to the initial copy number of target input
126 127 131in the sample , , (Figure 3). For a serial dilution of target this relation can be expressed 
as Ct = X log(N) + Y, in which ‘N ’ is the starting quantity, ‘X ’ is the slope of the curve, and 
‘Y ’ is the Y-intercept (Figure 3). With this calibration curve the starting quantity in an 
unknown sample can be calculated from its measured Ct-value.
Figure 3. A) Amplification plots of a serial dilution series of target. B) The linear relationship 
between the log of target input and cycle threshold values (Ct = -3.50 log (target) + 38.5).
The development of this new quantitative technique has opened numerous possibilities for 
quantification of (low) amounts of target (both DNA and RNA) in clinical samples. These
132 134 135 136 137targets can be virusses or micro-organisms " , gene amplifications , fetal DNA , ,
138 139 142methylated genes , or gene expression products " .
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Use of real-time quantitative PCR to compare 
DNA isolation methods
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PCR-based diagnostics of genomic DNA and DNA from viruses, microorganisms, or tumor 
cells are rapidly becoming routine practice in the clinical laboratory. DNA isolation is usually 
the first step toward detection. Because of expanding numbers of DNA isolation methods, the 
choice between methods is becoming increasingly difficult. Especially when a low amount of 
target DNA is present, when only a limited amount of clinical sample is available, or when 
PCR inhibitors are expected to be present, isolation efficiency, repeatability, and removal of 
PCR inhibitors by the isolation method become critical factors, seriously affecting the final 
outcome of the experiment.
Recently, a real-time quantitative PCR system [ABI Prism™ 7700 Sequence 
Detection System, Perkin-Elmer Applied Biosystems (PE)] was developed. Quantification is 
automatically performed in the exponential phase of the PCR reaction, where there is a linear
relationship between the log of input target DNA quantity and the number of PCR cycles to
1 2reach an arbitrary fluorescence threshold .
The objective of this study was to evaluate this PCR system for standardization of DNA 
isolation methods. Therefore, we added a known amount of marker DNA copies, close to the 
detection limit of the PCR, to plasma, which we chose because of recent developments in 
diagnostic molecular oncology 3,4 After isolating the DNA with four different methods, we 
used the PCR system to determine isolation efficiency and repeatability of each method.
Blood from five healthy donors was collected in 10-mL EDTA tubes. Plasma was 
pooled and stored at -80 °C.
A 12.8-kb plasmid containing a cDNA sequence construct of the bcr-abl gene 
translocation was used as marker DNA. The plasmid was linearized with a restriction enzyme, 
cleaned using a QIAquick column (QIAGEN), and quantified using GeneQuant II RNA/DNA 
calculator (Pharmacia). The marker was amplified with primers A24: 5' 
AAAGGTT GGGGTC ATTTTC AC 3' and BA5: 5' C GGGAGC AGC AG A AG A AGT GT 3' 
(316-bp fragment). We used bcr-abl: 5' (TET)-TCAGCGGCCAGTAGCATCTGACTT 
(TAMRA)p-3', where p indicates phosphorylation, as probe. Each 50-^L amplification 
reaction contained 5 |iL of sample, 5 |iL of 10x TaqMan buffer A (TaqMan PCR Reagent Kit, 
PE), 250 |imol/L each dNTP, 1.25 U of AmpliTaq Gold DNA polymerase (PE), 6 mmol/L 
MgCl2, 15 pmol of each primer, and 12.5 pmol of probe. MicroAmp optical tubes and caps 
(PE) were used to prevent light scattering or reflection. PCR cycling conditions were as 
follows: 10 min at 95 °C, followed by 50 two-step cycles of 95 °C for 30 s, and 60 °C for 90 
s. Emission spectra of all tubes were collected every cycle in the last 60 s of the primer 
annealing/elongation step. The system was directly linked to a Power Macintosh 7200/120
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(Apple Computer) containing software to program cycling conditions and analyze data. The 
number of PCR cycles to reach the fluorescence (Rn) threshold value is the cycle threshold 
(Ct) and is presented by the computer. The Ct value for each sample is proportional to the log 
of the initial amount of target DNA copies 5.
Because of the limited capacity of the thermal cycler, isolation experiments were 
performed on 2 consecutive days. To eliminate between-day variations in master mixture 
preparation, one master mixture was prepared for both days, which was possible because 
AmpliTaq Gold DNA polymerase is inactive without activation for 10 min at 95 °C. A 
calibration curve was constructed on both days by amplification of a duplicate 10-fold 
dilution series of marker DNA (50-500 000 copies). Within-run and between-day differences 
of the PCR system were measured by adding 1250 copies of marker DNA to sufficient PCR 
master mixture for 25 reactions each day (50 copies per PCR tube; Figure 1 , system). In two 
pilot studies of the characteristics of four DNA isolation methods, we observed that after 
applying the QIAamp blood kit (QIAGEN) no marker copies could be detected. This method 
was therefore omitted from the experimental design. For the other three DNA isolation 
methods, 25,000 copies of marker DNA were added to 25 mL of freshly thawed pooled 
plasma each day. The plasma was then divided into 50 reaction tubes (500 |iL each, 
containing 500 marker copies), which were used in 25 replicate DNA isolations by each 
method. Five microliters of each sample (10%, representing a maximum of 50 copies) was 
used for PCR (Figure 1, method).
Figure 1. Experimental design.
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Control samples were used for every DNA isolation method to determine the individual 
contribution of loss of marker and presence of PCR inhibitors/enhancers in the sample after 
isolation (Figure 1, control).
Four DNA isolation methods were used initially. Isolated DNA was always dissolved 
in or eluted with 50 |iL of 10 mmol/L Tris-HCl (pH 8.5).
In the PureGene DNA isolation kit (Gentra Systems) method, DNA was isolated as 
described previously 6; 60 |ig of glycogen was added after the protein digestion to facilitate 
DNA precipitation instead of poly[A] DNA.
In the PureGene DNA isolation kit + QIAquick column method, after PureGene DNA 
isolation, samples were further purified according to the "PCR purification protocol" provided 
with the QIAquick columns.
In the phenol-chloroform DNA extraction method, after overnight incubation at 55 °C 
with 100 ^L of protein digestion buffer (600 mmol/L NaCl, 60 mmol/L Tris-HCl, pH 8.0, 120 
mmol/L EDTA, 30 g/L sodium dodecyl sulfate, 200 |ig of proteinase K), samples were 
extracted twice with 600 |iL of phenol-chloroform-isoamyl alcohol (25:24:1, by volume), 
and DNA was precipitated with 1/10 volume of 3 mol/L sodium acetate and 1 volume of 
isopropanol. The DNA pellet was washed with 700 mL/L ethanol and dried.
In the QIAamp blood kit method, 500 |iL of AL buffer (provided in kit), 15 |iL of 
proteinase K (20 g/L), and 3 ^L of poly[A] DNA was added to the plasma samples. After 
overnight incubation at 55 °C, purification was performed according to the "blood and body 
fluid protocol" provided with the kit.
For all statistical analyses, the mean Ct values of each method were used to 
homogenize the variances. Because Ct values are proportionally related to the log of the copy 
number of marker, transformations were performed using a calibration curve. The calibration 
curves constructed on both days did not differ significantly (P <0.05) from each other, neither 
in slope nor in intercept (data not shown). The calibration curve of day 1 was therefore used 
to obtain point estimates for the median copy number of marker from corresponding mean Ct 
values (Ct = -3.444 x log[marker copies] + 38.510). In addition, mean Ct values of the system 
with corresponding standard deviations (presented in Table 1 as median copy number of 
marker with mean relative variance) did not differ significantly between days (Table 1 ). The 
median copy number of marker for the system is not exactly 50 copies because of the relative 
inaccuracy of the calibration curve. Because of the high repeatability of the system, we were 
able to compare the characteristics of isolation methods performed on 2 days.
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Table 1. Median marker DNA copies (95% CI) for the ABI Prism 7700 Sequence Detection 
System and different methods for the isolation of marker DNA from plasma.
Methods Day 1 Methods day 2
System0 PureGene PureGene+ System Phenol
(ABI 7700) QIAquick (ABI 7700) Chloroform
Method"
median 4 Os S
s- 33" 16J 47 24e
(95%CI) (43 ; 49) (28 ; 39) (15 ; 17) (43 ; 51) 8)2(21
n 25 25 25 25 25
mean relative 0.228f 0.639g 0.274f 0.305f 0.549g
variance
Control"
median NAh 51 26 NA 70
(95%CI) (37 ; 68) (16 ; 44) 8)2(4
n NA 5 4 NA 5
Relative loss'
median NA 35% 38% NA 66%
(95%CI) (11% ; 52%) (-3% ; 63%) (43% ; 79%)
n 5 4 5
Relative inhibition
median NA -10% 43% NA -52%
(95%CI) (-47% ; 19%) (6% ; 66%) (-153% ; 8%)
n 5 4 5
a See Fig. 1
b'e Same letters indicate no statistically significant difference in median copy numbers between methods (Welch 
test/t-test)
fg Same letters indicate no statistically significant difference in mean relative variance of copy numbers between 
methods (Bartlett’s test) 
aNA, not applicable
' Relative change of marker copies lost during isolation 
J Significantly different from 0% (Welch-test)
1 Relative change of marker copies caused by the presence of PCR inhibitors. Note that negative values indicate 
the presence of PCR enhancers in the sample.
Power analyses showed (using data of pilot studies) that at least 20 measurements 
were needed to obtain a power of 90% for detecting statistically significant differences when 
the ratio of the repeatability standard deviations equals two ( = 0.05). Differences in the mean 
Ct values between two methods were tested for statistical significance using the t-test in case 
of equal variances and the Welch test in case of unequal variances and are presented in Table 
1 as median marker copies after back transformation. Differences between standard deviations 
of the Ct measurements of two methods were tested for statistical significance using the 
Bartlett test and are presented as mean relative variance values. Differences in Ct values 
between method and control and between system and control, representing loss and inhibition,
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respectively (Figure 1 ), were tested using the Welch test and are presented as relative loss 
and relative inhibition values of the median copy number of marker (Table 1).
Significant differences in the performance (isolation efficiency and repeatability) were 
found between methods. Moreover, information was obtained about the contribution of copy 
number loss and PCR inhibitors or enhancers to this performance (Table 1). When the median 
copy number of marker of the system (day 2) is used as denominator, isolation efficiencies 
were 70% (95% CI, 60-83%), 34% (95% CI, 32-36%) and 51% (95% CI, 45-60%) for the 
PureGene, PureGene QIAquick, and phenol-chloroform methods, respectively; all methods 
were significantly different from each other as well as significantly different from the system. 
Precision (mean relative variance) of the PureGene + QIAquick method (0.274) was similar to 
that of the system and significantly lower than that of the PureGene and phenol-chloroform 
methods. Relative losses of marker DNA copies were 35%, 38%, and 66% for the PureGene, 
PureGene QIAquick, and phenol-chloroform methods, respectively. For the PureGene and 
especially the phenol-chloroform methods, this loss was partially compensated by the 
presence of PCR enhancers (-10% and -52% inhibition, respectively). Although the PureGene 
method has the highest isolation efficiency, it has a relatively poor precision. Use of a 
QIAquick column after PureGene isolation markedly decreased the isolation efficiency (from 
70% to 34%); however, it simultaneously increased the precision to a value equal to that of 
the system. Because there was not much additional relative loss when the QIAquick column 
was used (35% vs 38%), this suggests that the column removes variable amounts of PCR 
inhibitors/enhancers still present in the sample after PureGene DNA isolation, although the 
number of control samples should be enlarged to confirm this statistically. At the same time, a 
constant amount of PCR inhibitors is introduced, probably by one of the buffers in the 
QIAquick kit. An extra column washing step or the use of another column washing buffer 
may eliminate these PCR inhibitors and could make this method very robust. The additional 
use of a column can be especially advantageous when using plasma samples of patients, 
which will probably contain more diverse amounts of PCR inhibitors or enhancers than the 
pooled plasma of healthy donors used in this study.
The QIAamp method had very poor isolation efficiency in our pilot studies when only
8 9few copies of marker DNA were present, consistent with other studies ’ . Although our 
results for plasma appeared to conflict with a study performed by Dixon et al. 10, where the 
QIAamp method was their first choice of 13 tested DNA isolation methods from patient sera 
(considering DNA isolation from serum equal to plasma), both studies cannot be compared 
because genomic DNA copy numbers in sera from cancer patients are expected to be much
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higher than the copy number of marker used in our study ’ . Moreover, in their study ~50% 
of the sera that were "PCR negative" after the QIAamp method could be PCR amplified after 
application of another DNA isolation method. This indicates that efforts to improve isolation 
efficiency (loss, removal of inhibitors) using other DNA isolation methods may still be 
successful, especially when dealing with low copy numbers of target DNA.
With this in-depth analysis of several DNA isolation methods, we try to emphasize 
that a well-considered choice is very important for standardization of PCR-based diagnostics 
when only a limited amount of target DNA may be present in a clinical sample. In conclusion, 
because of its high repeatability, its closed tube system, which reduces PCR product 
contamination and assay time, and the ability to gain information about the performance of 
DNA isolation methods, real-time quantitative PCR performed by the ABI Prism 7700 
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Abstract
Circulating tumor DNA has previously been detected in serum and plasma of patients with 
lung cancer and head and neck cancer. These observations could potentially lead to new, 
specific and non-invasive tools for diagnosis, prognosis and follow-up in neoplastic disease, if 
found to be a more general phenomenon. To test if tumor DNA is also present in serum of 
patients with colorectal cancer, we selected fourteen colorectal cancer patients with advanced 
disease. In seven patients, K-ras mutations were detected in the primary tumor, using mutant- 
specific primers for point mutations in codon 12 or 13 of the K-ras gene. All patients were 
analysed for mutant DNA in serum. Tumor-specific point mutations, corresponding to the K­
ras mutations found in the primary tumor were detected in serum of all patients but one. No 
mutant K-ras could be detected in serum of seven patients without K-ras mutations in the 
primary tumor. These results may be useful in assessing tumor burden in patients with 
neoplastic disease. Moreover, consecutive testing of serum tumor DNA after surgery or 
chemotherapy may be used as a tumor marker for recurrent disease.
Introduction
Detection of free circulating tumor DNA in serum of cancer patients offers new possibilities 
for cancer diagnostics. Recently, sensitive polymerase chain reaction (PCR) based assays
have been used to detect mutated tumor DNA sequences in the serum or plasma of patients
1 2with lung cancer and head and neck cancer ’ . Circulating tumor DNA was predominantly 
found in patients with advanced disease and in those with poor prognosis. It was suggested 
that analysis for circulating tumor DNA might be useful in tumor staging and might help to 
identify patients at risk of tumor recurrence . These findings are provocative and call for 
further investigation in other types of cancer.
Mutations in codon 12 or 13 of the K-ras gene occur in 40-50% of all colorectal 
cancers. The detection of these mutations against a background of normal DNA requires 
highly sensitive and properly validated assays. Mutant allele specific amplification (MASA) 
by PCR utilises the inability of Taq polymerase to elongate a primer when the 3’ end of the 
primer mismatches the template and can therefore be used to selectively amplify mutated
4sequences .
In this study, patients with advanced colorectal cancer were evaluated for circulating 
mutant tumor DNA in their serum. Analyses were based on the detection of point mutations 
of the K-ras gene in serum by MASA.
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Materials and Methods
Fourteen patients with advanced colorectal cancer (Dukes D) were selected.
Six 8 ^m, formalin fixed, paraffin embedded tissue sections of the colorectal primary 
were placed into an Eppendorf tube. Six hundred ^l cell lysis solution (Puregene, Gentra 
systems, Research Triangle Park, NC, USA) was added and heated for 10 min at 80°C in a 
thermomixer (Eppendorf, Hamburg, Germany). After centrifugation for 1 min at 23,900 x g, 
10 ^L proteinase K (20 mg/ml)(Boehringer Mannheim GmbH, Mannheim, Germany) was 
added and protein digestion was performed overnight at 55°C in a thermomixer. Samples 
were further processed according to the manufacturers protocol for DNA isolation from tissue 
(Puregene). DNA content was quantified spectrophotometrically and 5 ^L, containing 300 ng 
DNA, was used for MASA.
Blood was collected in Corvac tubes (Sherwood Medical, Ballymoney, N.Ireland). 
After clotting, tubes were centrifuged for 10 min at 2,000 x g and serum was stored at -80°C 
until use.
DNA isolation from serum samples was performed using a modified protocol for DNA 
isolation from body fluids according to the Puregene instructions. Briefly, 500 ^L serum was 
added to a 1,5 mL Eppendorf tube containing 500 ^L cell lysis solution (Puregene), 10 ^g 
poly[A] DNA (Sigma, Zwijndrecht, The Netherlands) and 15 ^L proteinase K (20 mg/mL). 
After protein digestion overnight at 55 °C in a thermomixer, samples were cooled on ice. Two 
hundred ^L of protein precipitation solution was added and the samples were incubated on ice 
for 15 min after mixing. Proteins were pelleted by centrifugation for 3 min at 23,900 x g. 
DNA was precipitated with isopropanol, washed once with 70% ethanol and dissolved in 50 
^L 10 mM Tris-HCl (pH 8.5). Five ^L was used for MASA.
MASA was performed using 20 pmol of each primer, 50 ^M of each dNTP, 2.5 mM 
MgCl2, 1 U AmpliTaq Gold (Perkin Elmer Corporation, Foster City, California, USA), 5 ^L 
10 x PCR II buffer (Perkin Elmer) and 5 ^L sample in a total volume of 50 ^L. An initial 
sample denaturation and polymerase activation step at 94°C for 10 min was followed by 35 
cycles of 94°C for 1 min, 60°C for 30 s, 72°C for 45 s and a final extension of 10 min at 
72°C. MASA forward primers for mutant K-ras amplification were identical to those used by 
Hasegawa et al 4 Primer #103, 5’-actcatgaaaatggtcagagaaacctttat was used as antisense 
primer. PCR products (178 bp) were separated on a 2% agarose gel (Boehringer Mannheim 
GmbH) in 0.5 x TAE buffer.
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Serum and tumor tissue of fourteen patients with colorectal cancer were analysed for point 
mutations in codon 12 and 13 of the K-ras gene. All patients had systemic disease. Seven 
patients were positive for K-ras mutations in the primary tumor. For all positive patients but 
one, point mutations in the K-ras gene were present in the serum (Figure 1), identical to the 
mutations detected in the corresponding primary tumor. Patients with no K-ras mutation in 
the tumor, were negative for mutant K-ras in serum. To assess the specificity of the method, 
all MASA primers (four sets of three primers matching the first two nucleotides of codon 12 
and 13) were tested on serum of these patients (data not shown). The method is highly 
specific for mutant K-ras and no false positive signals due to break through of mutant-specific 
primers have been detected.
Results
M 1 2 3 4 5 6 7 8 9 M
Figure 1. PCR amplification of mutant K-ras DNA isolated from serum of colorectal cancer 
patients. Lanes M, 50 bp DNA ladder. Lanes 1 to 7, mutant allele specific amplification on 
DNA isolated from serum of 7 colorectal cancer patients with K-ras mutations in the primary 
tumor. Lane 8, no template control. Lane 9, 100 ng DNA from SW480, a mutated K-ras cell 
line (positive control).
Discussion
In this study we demonstrate the presence of tumor-specific DNA in the serum of patients 
with advanced colorectal cancer. These results, in a group of patients with a common type of
12 5cancer, consolidate previously published data ’ ’ .
Despite the high sensitivity of the MASA, in one patient no K-ras mutation could be 
detected in serum, although the primary tumor in this patient was positive for mutated K-ras. 
It has been reported that metastatic lesions may be genetically different compared to the 
primary tumor they originate from, due to the presence of heterogeneous clones 6,7 This could 
possibly explain the findings in this particular patient, indicating that the use of more than one 
tumor marker may be necessary to obtain higher sensitivity.
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Analysis of free plasma tumor DNA could potentially be an attractive diagnostic and 
prognostic tool in patients with colorectal cancer. Recently, Anker et al. reported the presence 
of K-ras mutations not only in the plasma of patients with Dukes D, but also in three patients 
with Dukes A, B and C stages of colorectal cancer, using a nested PCR technique 5. These 
results suggest that circulating tumor DNA sequences may be used for early detection of 
colorectal neoplasms. If free serum or plasma tumor DNA proofs to be a reliable indicator of 
systemic disease (instead of early disease) at the time of surgery for the colorectal primary 
tumor, it would enable clinicians to identify patients with poor prognosis who are at risk for 
tumor recurrence after surgery. This would improve staging and hence selection of those 
patients who would benefit most from adjuvant chemotherapy. Moreover, consecutive testing 
for the presence of free serum tumor DNA in the follow-up after surgery, could be used as a 
tumor marker for recurrent disease. Although our results are preliminary, they do validate 
efforts to further investigate the potential usefulness of tumor DNA in serum in the diagnosis, 
staging and follow-up of patients with colorectal cancer.
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Clinical value of bile for the detection of mutant K-ras from
colorectal liver metastases
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Abstract
In 25% of patients diagnosed with colorectal cancer, hepatic metastases are not detected at 
presentation of the colorectal primary but develop during follow-up. Early detection of these 
metastases may improve the chance of cure by surgical resection. We hypothesized that in 
patients with occult hepatic metastases, tumor DNA might be detected in bile which could be 
collected during resection of the colorectal primary. To test this hypothesis, bile from the gall 
bladder was collected from 17 patients scheduled for resection of evident hepatic metastases
3
(>2 cm ) from a previously resected colorectal primary. Mutation analysis of the metastases 
identified five patients (34%) with a K-ras gene mutation in the tumor tissue. These cases 
were selected for bile analysis for mutant K-ras. Nonmutated DNA could be amplified from 
all the bile samples, but mutant K-ras could only be detected in bile from one patient. False 
negative results due to technical deficits could be ruled out by control experiments showing 
high DNA isolation efficiency and high sensitivity of the mutation detection method. It is 
concluded that hepatic metastases, in contrast to pancreatic cancers, do not (regularly) shed 
mutated DNA into the bile. Hence, molecular screening of bile seems of only limited clinical 
value for the detection of occult liver metastases.
Introduction
Colorectal cancer (CRC) is the second most common cancer in the western world 1. After 
surgical resection, 5-year survival is approximately 50% with liver metastases forming the 
main cause of death. Twenty to 25% of the patients show detectable liver metastases at the 
time of diagnosis of the colorectal primary. Another 25% will develop metachronous liver
2 3metastases usually within 2 years after the tumor resection 2,3. In the latter group of patients 
the detection of occult metastatic liver disease at the time of resection of the colorectal 
primary could improve survival. Patients with occult metastatic liver disease could either be 
treated with more intensive chemotherapy protocols, or follow-up could be intensified in 
order to resect metastatic deposits as soon as they become radiologically evident.
Several studies have been performed in order to identify patients with possible occult 
metastatic disease. For example, Leen et al. 4 showed that the hepatic perfusion index, which 
is the ratio of hepatic arterial flow to total liver blood flow, is raised in patients with colorectal 
cancer at risk of developing liver metastases. Others have suggested that a carcinoembryonic 
antigen (CEA) measured in the bile might be a marker to detect liver metastases at an early 
stage. It was proposed that CEA could be shed into the bile by tumor cells in the liver and was 
concentrated twelve-fold by the gall bladder 5.
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Recent advances in molecular diagnostics have opened up new perspectives with 
regard to the detection of free mutated tumor DNA in body fluids 6-10. For instance, K-ras 
gene mutations could be detected in the bile of 70% of patients with pancreatic cancer 6, 
indicating that DNA (or cells) was shed from the tumor into the bile and could still be 
detected after exposure to bile salts and digestive enzymes. We hypothesized that occult 
hepatic metastases may also shed free tumor DNA or tumor cells into the bile. Since bile can 
relatively easy be obtained during resection of the colorectal primary, mutation detection in 
bile may be used as a possible early marker for liver metastases. To test this hypothesis, first 
patients with evident hepatic metastases containing a K-ras mutation were selected for bile 
analyses. We investigated whether the K-ras mutation found in the tumor could be detected in 




Seventeen patients scheduled for resection of hepatic metastases (> 2 cm ) from a previously 
resected primary CRC were selected for bile and tumor tissue collection after informed 
consent. During surgery, the gall bladder was punctured with a 0.6 mm needle and 5 ml of 
bile was taken. Contamination with blood during puncture was carefully avoided. The bile 
was centrifuged for 10 minutes at 2800 xg. Supernatant and pellet were processed separately 
to be able to distinguish between the presence of mutated free DNA and shedded whole 
cancer cells. To 500 ^l of the supernatant, 500 ^l of Cell Lysis Solution (PureGene Kit, 
Gentra systems, Research Triangle Park, NC, USA) was added and stored at 4°C. The bile 
pellet was washed once with PBS and 300 Cell Lysis Solution was added before storage at 
4°C. The duration between collection of bile during surgery and storage never exceeded 1 
hour.
Mutation detection in tumor tissue
After surgery, DNA was isolated from paraffin sections of the hepatic lesions using the 
PureGene Kit as previously described 10. Subsequent mutant allele specific amplification 
(MASA) of codons 12 and 13 of K-ras gene was performed 10.
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DNA isolation and mutation detection in bile
To the stored bile supernatant and bile pellet samples, 10 ^l of proteinase K (20 mg/ml) was 
added. After protein digestion overnight at 55 °C in a thermomixer, samples were cooled on 
ice. To bile supernatant and bile pellet samples, 150 ^l and 100 |il of protein precipitation 
solution were added, respectively. The samples were incubated on ice for 15 minutes after 
mixing. Proteins, if  present, were pelleted by centrifugation for 3 minutes at 23,900 x g. To 
the supernatant, 3 ^l of glycogen (20 mg/ml) was added as DNA precipitation carrier together 
with isopropanol and incubated for another 30 minutes on ice. After centrifugation for 5 
minutes at 23,900 x g, the DNA pellet was washed once with 70% ethanol, dried and 
dissolved in 50 ^l 10 mM Tris-HCl (pH 8.5). Samples were further purified using QIAquick 
columns (Qiagen, Hilden, Germany) according to the “PCR purification protocol” provided 
with the QIAquick kit. DNA was eluted from the column using 50 ^l 10 mM Tris-HCl (pH 
8.5) preheated to 70°C. For PCR, 5 ^l of sample was used.
Two different PCR’s were performed on isolated DNA from bile. First, the total K­
ras gene (wildtype + mutated) was amplified as a DNA quality control. Primers #100: 5’ 
TGTGGTAGTTGGAGCTG 3’ and #103: 5’ACTCATGAAAATGGTCAGGAAACCTTTAT 
3’ were used. PCR was performed using 20 pmol of each primer, 50 ^M  of each dNTP, 2.5 
mM MgCl2, 1 U AmpliTaq Gold (Perkin Elmer Corporation, Foster City, California, USA), 5 
|lL 10 x PCR II buffer (Perkin Elmer) and 5 ^L sample in a total volume of 50 ^L. An initial 
sample denaturation and polymerase activation step at 95 °C for 10 minutes was followed by 
35 cycles of 95 °C for 30 s, 60°C for 30 s, 72°C for 45 s and a final extension of 7 minutes at 
72°C. PCR products (177 bp) were separated in a 2% MetaPhor agarose gel (FMC 
Bioproducts, Rockland, ME, USA) and stained with ethidium bromide.
Secondly, MASA was performed on the bile DNA samples using forward primers for 
mutant K-ras amplification identical to those used by Hasegawa et al. 11. Primer #103 was 
used as antisense primer. MASA conditions were identical to total K-ras amplification.
Sensitivity of the DNA isolation and mutation detection method
To determine sensitivity of the methods used for DNA isolation and mutation detection, a 10­
fold dilution series of mutant K-ras DNA (240 pg -  24 ng), isolated from the SW480 
colorectal cancer cell line (mutation in codon 12; ggt ^  gtt), was added to bile samples from 
3 patients without a K-ras gene mutation in the tumor. After DNA isolation, 5 ^l of the DNA 
(10%) was used for MASA with primers specific for the ggt ^  gtt mutation. Fifteen ^l of the
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MASA product for each dilution was loaded on an agarose gel (2%) and stained with 
ethidium bromide.
Results
Selection of patient samples
All 17 patients were analyzed for the presence of K-ras mutations in the tumor tissue. In five 
patients the tumor tissue contained a K-ras mutation. None of these five tumors contained 
more than one mutation. Two patients had an identical K-ras mutation in the tumor whereas 
the other three had different mutations (data not shown). All 5 patients were selected for bile 
analysis.
Validation of methods
To determine whether intact DNA could be isolated from pure bile, bile specimens were 
analyzed for the presence of total K-ras (wildtype + mutant). In all five patients K-ras could 
be amplified from the bile supernatant as well as from the pellet, indicating that DNA can be 
extracted successfully from gallbladder bile using our method (Figure 1).
To establish the sensitivity of the DNA isolation and mutation detection method, bile 
specimens were spiked with a dilution series of mutant DNA (SW480 cell line) and 
subsequently amplified after DNA isolation using the corresponding MASA primer for 
SW480 DNA. The sensitivity limit of our method was about 24 pg of mutant DNA which is 
equivalent to 4 cells (Figure 2A). This sensitivity was equal to a dilution series of mutant 
SW480 DNA directly added to the MASA within and without the presence of 100 ng non­
mutated DNA (Figure 2B).
M 1 2 3 4 5 6 7 8 9 10 - + M
Figure 1. Total K-ras amplification of DNA isolated from bile supernatant and pellet of 5 
patients. Lanes 1-2, 3-4, 5-6, 7-8, 9-10 correspond to patients 1 to 5, respectively. Odd lanes 
correspond to DNA isolated from bile supernatant and even lanes correspond to DNA 
isolatedfrom bilepellet. Lane -; PCR blank. Lane +; genomic DNA as positive control. Lanes 
M; 50 bp DNA ladder.
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M 1 2 3 4 M 5 6 7 8 M 9 10 11 12
B.
M 1 2 3 4 M 5 6 7 8
Figure 2. Sensitivity of the DNA isolation and mutation detection method.
A. A 10-fold dilution series of mutant K-ras DNA (SW480 cell line) was added to bile of three 
patients without a K-ras mutation in the tumor. Mutant allele specific amplification was 
performed on the isolated DNA. Patients are separated by lanes M  (50 bp DNA ladder). 
Lanes 1, 5, and 9; no mutant DNA added (negative controls). Lanes 2, 6, and 10 represent a 
maximum of 24 pg mutant DNA input in the PCR. Lanes 3, 7 and 11 represent a maximum 
240pg input. Lanes 4, 8, and 12 represent a maximum of 2.4 ng input.
B. A dilution series of mutant K-ras DNA was directly added to the PCR. Lanes 1-4; 0, 24 pg, 
240 pg, and 2.4 ng added, respectively. Lanes 5-8; the same dilution series added as in 1-4 
but in thepresence of 100 ng wildtype DNA.
Detection of mutant K-ras in bile
After evaluation of the DNA isolation and mutation detection methods, bile samples were 
analyzed for K-ras mutations using four MASA primers corresponding to the four mutations 
found in the five tumors. If mutant DNA was present in the bile, mutant allele specific 
amplification was expected for only one primer, whereas the other three primers served as 
controls for false positivity (specificity). After DNA isolation, mutated K-ras identical to the 
tumor could be detected in both supernatant and bile pellet of only one patient (Figure 3, 
patient 4). In this patient the other three MASA primers, not corresponding to the mutation in 
the tumor, did not generate a PCR product (data not shown). Mutated K-ras could not be 
detected in any of the bile samples of the other four patients, despite the high sensitivity of the 
detection method (Figure 3, patient 1).
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1 2 3 M 4 5 6 M
Figure 3. Detection of mutant K-ras in tumor and bile ofpatients with hepatic metastases 
containing a K-ras mutation. Lanes 1-3; mutant allele specific amplification on DNAfrom 
tumor, bile supernatant, and bile pellet, respectively,from patient 4. Lanes 4-6; identical 
orderforpatient 1. Lanes M; 50 bp DNA ladder.
Discussion
Five out of 17 (34%) liver metastases from colorectal cancer contained a K-ras mutation. This
12 13frequency is similar to other studies ’ . Although all the patients in our study had gross 
hepatic metastases, mutant DNA could only be detected in the bile from 1 out of 5 (20%) 
patients with K-ras mutated tumors. This finding is in contrast to the findings from the bile of 
patients with pancreatic malignancies in which K-ras mutations could be detected in 14 of 20 
(70%) patients 6.
Three possibilities may be considered as explanation of this low sensitivity. First, 
DNA shed in the bile may be rapidly degraded in the gall bladder or during storage. In all the 
bile samples, however, total K-ras could be amplified indicating the presence of non­
degraded DNA. This was confirmed by other studies. After addition of free DNA to bile, 
Ajiki et al. 14 could still amplify DNA exposed for 12 hours. Others were able to detect 
mutant K-ras DNA in the bile of patients with pancreaticobiliary malignancies 6’15. We also 
could detect mutated DNA in bile of one patient. This suggests that fast DNA degradation in 
bile does not occur and hence is not likely to explain our results.
The second possibility is that our DNA isolation and mutation detection method 
lacked sensitivity. In the spiking experiments we were able to detect 4 mutant cells or mutant 
DNA equivalents after 35 PCR cycles. This indicates that isolation efficiency was near 100% 
and no PCR inhibitors were present after the use of the QIAquick column to purify the 
isolated DNA.
The third and most likely explanation of our results is that liver metastases do not 
(regularly) shed tumor DNA or tumor cells into the bile in quantities high enough to be 
detected by molecular diagnostic tests. Even though our patient group was small, we had 
expected to detect K-ras mutations in at least 4 of 5 bile samples from patients with evident 
metastatic deposits to make testing useful for patients with occult disease. We therefore
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conclude that in patients with possible occult metastatic disease, molecular diagnostic testing 
of mutated DNA from bile will be of no benefit for early detection.
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Chapter 5
Early detection of leptomeningeal metastasis by PCR examination 
of tumor-derived K-ras DNA in cerebrospinal fluid
Dorine Swinkels, Jacques de Kok, Anton Hanselaar, Karel Lamers, and Rudolf Boerman
51
Intoduction
Leptomeningeal metastasis (LMM) occurs in 3-8% of all cancer patients. Of the solid tumors, 
breast cancer, lung cancer, and malignant melanoma are the most common to metastasize to 
the leptomeninges 1. The prognosis for patients with LMM is poor; most individuals surviving 
a median of only about four months. Early diagnosis may improve the clinical response to 
radiotherapy and (intrathecal) chemotherapy, and may lead to more effective palliation and 
prolonged survival 1.
Traditionally, a definitive diagnosis of LMM requires cytological detection of 
malignant cells in the cerebrospinal fluid (CSF). Interpretation is often aided by 
immunocytochemical techniques. Unfortunately, these CSF samples often contain very few 
malignant cells that can be identified morphologically. In these cases no definitive diagnosis 
can be established, resulting in “suspicious” or “atypical” diagnoses 1.
Molecular detection of tumor-derived DNA in CSF may improve early and sensitive
2 3detection of LMM because no intact cells are required for diagnosis , . Here, we report the 




CSF was collected from 4 patients at initial clinical presentation of LMM and from 3 patients 
with non-malignant diseases (Multiple Sclerosis, Alzheimer, and Meningitis). CSF was 
centrifuged and the pellet of the 4 patients with LMM was sent to the pathology department 
for cytological analysis. DNA was isolated from 500 ^l of the supernatant as described earlier 
for serum 4 DNA was further purified using a QIAquick column (QIAGEN) and stored at - 
20°C until analysis. DNA was also isolated from the primary lung tumors of the 4 patients 
with LMM 4.
K-ras gene amplification
Mutant allele specific amplification (MASA) was used to detect all possible mutations in 
codon 12 of the K-ras oncogene. Forward primers were developed by Hasegawa et al. 5. 
Primer #100, corresponding to the nonmutated codon 12 of K-ras was used as forward primer 
for amplification of wildtype K-ras. Primer #103: 5’-ACTCATGAAAATGGTCAGAGAAA- 
CCTTTAT-3’ was used as reverse primer. All PCR reactions were performed with 20 pmol of 
each primer, 2.5 pmol of each dNTP, 2.5 mM MgCl2, 1 U AmpliTaq Gold (Perkin Elmer), 5
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^l 10x PCR II buffer (Perkin Elmer), and 5 ^l sample in a total volume of 50 ^l. After an 
enzyme activation step of 95°C for 10 minutes, 35 cycles were performed: 95°C for 30 s., 
60°C for 30 s. and 72°C for 45 s.
First, the presence of wildtype DNA was identified in all samples. Second, the 
presence of a K-ras mutation in the samples was tested using two sets of primers 
corresponding to all possible mutations in nucleotide 1 and 2, respectively. Whenever one 
primer set amplified mutant DNA, the primers in this set were individually tested on the 
sample to identify the exact nature of the mutation. PCR products were separated on agarose 
(2%) and stained with ethidium bromide.
Results
The primary tumors (adenocarcinoma of the lung) of two patients (A and B) contained a K­
ras mutation (Figure 1A). Both tumors had metastasized to the cerebellum. Treatment 
consisted of resection of the metastatic tumor followed by radiotherapy. Clinically suspected 
LMM emerged 24 weeks (patient A) and 2 weeks (patient B) after the resection.
A. B.
M 1 2 3 4 5 6 M M 1 2 3 4 5 6 M
Figure 1. Detection by MASA of mutant K-ras in the lung adenocarcinoma (A) and the 
cytologically negative CSF (B) of a patient with clinical features of LMM.
(A), MASA performed on DNA isolated from the tumor ofpatient B. Lane 1, amplification of 
wildtype K-ras; lanes 2 and 3, initial K-ras mutation screening using two PCR mixtures, each 
containing three MASA primers to detect all codon 12 mutations at nucleotide positions 2 and 
1, respectively; lanes 4-6, split up of the three MASA primers specific for codon 12, 
nucleotide 1. (B), MASA performed on DNA isolated from the CSF of patient B (lanes 1-3) 
and a cell line containing K-ras wildtype alleles (lanes 4-6). Three different PCR forward 
primers were used for specific amplification of) wildtype K-ras (GGT, positive control; lanes 
1 and 4), the AGT mutation (MASA specificity control; lanes 2 and 5), and the TGT mutation 
(lanes 3 and 6) as found in th tumor (Fig 1A, lane 6). M, 50 bp DNA ladder.
Patient A experienced radicular pain in both arms. Although MRI scanning revealed 
LMM, cytology of the fist CSF specimen was negative. It was only 4 weeks after this initial 
investigation, at the second CSF puncture, that malignant cells could be detected.
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Patient B suffered from radicular pain in both legs and diplopia. The clinically 
suspected LMM could not be confirmed by cytological examination of the CSF. After 11 
weeks, patient B had developed an organic psychiatric syndrome and multifocal 
radiculapathy. At that time, a second CSF examination was diagnostic for LMM.
The CSF of both patients A and B was collected at initial clinical presentation of 
LMM. A K-ras mutation identical to the tumor could be detected in the supernatant (Figure 
1B). Other K-ras mutations were absent. In the controls, including the two patients without a 
K-ras mutation in the primary tumor, no mutant K-ras could be detected in the CSF (Figure 
2).
M 1 2 3 4 5 6 7 8 9 10 M M 11 12 13 14 15 16 17 18 M
Figure 2. Detection of wildtype and mutant K-ras in CSF of control patients. Lanes 1 to 5, 
amplification of wildtype K-ras in CSF from 2 patients with LMM (without mutant K-ras in 
the tumor) and 3 patients with non-neoplastic disease (multiple sclerosis, meningitis, 
Alzheimer’s disease), respectively. Lanes 6 to 10, MASA for mutant K-ras codon 12, 1th 
nucleotide for the same order of patients. Lanes 11 to 15, MASA for mutant K-ras codon 12, 
2nd nucleotide. Lane 16, positive PCR control for mutant codon 12, 1th nucleotide (cell line 
SW1398). Lane 17, positive PCR control for mutant codon 12, 2nd nucleotide (cell line 
SW480). Lane -, PCR blank. Lanes M ,50 bp DNA marker.
Discussion
Detection of K-ras mutations in the CSF of clinically suspected LMM-patients is a promising 
tool for early diagnosis, follow-up and treatment-monitoring of LMM derived from primary 
adenocarcinoma of the lung. Moreover, with sensitive methods such as MASA, it is relatively 
easy to screen for K-ras point mutations in the CSF supernatant, which is not used for 
cytology, even without previous knowledge of the tumor mutations.
In this study we could not exclude that the mutated DNA detected in the CSF 
originated from the serum of these patients. It is unknown whether free circulating DNA, 
probably complexed to nucleoproteins 6,7, can cross the blood-brain barrier in cancer patients 
with systemic disease. Additional experiments are needed to confirm specificity, for instance 
in the CSF and serum of patients with K-ras mutated tumors without brain metastases.
Since K-ras mutations are found in only 30% of the adenocarcinoma of the lung , and 
are rare in other solid tumors which frequently metastasise to the leptomeninges 9, additional 
molecular markers for the management of LMM are of potential interest 10,11.
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Real-time hTERT quantification: a promising telomerase- 
associated tumor marker
Jacques de Kok, Han Zendman, Louis van de Locht, Theo Ruers, Goos van Muijen, Ewald
Mensink, and Dorine Swinkels
S7
Telomerase activity has been found in more than 85% of human tumors and is the most 
common tumor marker so far 1. Two subunits essential for a functional telomerase enzyme 
have been cloned, hTR and hTERT, of which hTERT is the rate limiting determinant of
2,3telomerase activity , . We have developed a quantitative assay for the measurement of 
hTERT expression using real-time quantitative PCR. The hTERT expression was normalized 
to the amount of RNA input using 18S ribosomal RNA (rRNA) expression, which also served 
as an endogenous control. Using a panel of tumor cell lines, primary cell cultures and normal 
tissues, the assay could determine small differences in hTERT expression. Our quantitative 
data are consistent with semi-quantitative telomerase activity (TRAP assay) measurements.
RNA from cultured cells was isolated with the RNeasy Kit (QIAgen, Hilden, 
Germany) using the manufacturer’s protocol. RNA from normal human tissues was isolated 
by disruption of 25 frozen, 20 ^m sections in 1 ml RNAzolB (Biotex Laboratories Inc., 
Houston, TX) using a pestle. After completing the manufacturer’s protocol, RNA was further 
purified using the RNeasy Kit. RNA was quantified spectrophotometrically. Each sample, 
containing approximately 0.2 -  1.0 ^g RNA, was supplemented with RNase-free water to 10 
^l and denatured for 5 minutes at 90°C. cDNA synthesis was performed for 10 minutes at 
20°C, 45 min at 42°C, and 10 min 95° with first strand buffer (Life Technologies BV, Breda, 
The Netherlands), 200 U MMLV (Life Technologies), 20 U Rnasin, 10 mM DTT, 4.75 ^M 
random hexamers, and 600 ^M deoxynucleotides in a total volume of 20 ^l.
The principle of the real-time PCR is explained by Heid et al 4 and Mensink et al 5. A cDNA- 
specific real-time PCR assay was developed for quantification of hTERT. We used 900 nM of 
primer LT5, 300 nM of primer LT6 2 and 100 nM probe (TET- 
TTGCAAAGCATTGGAATCAGACAGCACT-TAMRA), which is located between 
nucleotides 1805-1832 (Genbank accession number AF015950), together with 25 ^l of 
TaqMan Universal Master Mix (Perkin-Elmer, Foster City, CA) and 1 ^l of the RT reaction in 
a total volume of 50 ^l. After enzyme activation for 10 minutes at 95°C, 38 two-step cycles 
were performed (30 seconds, 95°C; 1 minute, 60°C). All samples were measured three times 
in separate experiments.
The level of rRNA expression was quantitatively measured in each sample as 
normalization for sample to sample differences in RNA input (spectrophotometry has a 
relatively low precision), RNA quality, and RT efficiency. In preliminary experiments we also 
quantified expression levels of the genes porphobilinogen deaminase (PBGD) and 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) next to rRNA as normalisation
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controls. Especially for tumor cell lines, normalized hTERT values using these housekeeping 
genes were lower, probably because of up-regulation of these genes during tumor 
development. Therefore, we chose the expression of rRNA as normalisation control. The 
rRNA primers and probe were obtained from the TaqMan ribosomal RNA control reagents 
Kit (Perkin Elmer). To prevent low Ct values of rRNA measurements from interfering with 
calculations of the threshold baseline, both samples and the dilution series for the calibration 
curve were diluted 20-fold before all rRNA cDNA measurements. Amplification conditions 
for rRNA were identical to those for hTERT. All samples were also measured three times in 
separate experiments.
For the preparation of the dilution series for the calibration curve we chose the T24 
bladder carcinoma cell line because of its high hTERT expression. After cDNA synthesis, a 
five-fold cDNA dilution series (50-0.08 ng) was measured during every experiment in 
duplicate for both hTERT and rRNA. Between experiments, the calibration curves for each 
gene did not differ significantly from each other, neither in slope nor in intercept. Typical 
functions were Ct (hTERT) = -3.71 log [hTERT] + 33.84 and Ct (rRNA) = -3.63 log [rRNA] 
+ 18.93 (r > 0.99 for all curves). The cycle threshold (Ct) values of all samples were 
measured by the ABI Prism 7700 sequence detection system (Perkin Elmer [PE]) and were 
transformed to nanograms of T24 hTERT and T24 rRNA using the measured calibration 
curves in the same experiment. The ratio (in %) between nanograms of hTERT and rRNA 
represents the normalized hTERT expression for each sample and can be directly compared to 
that of other samples (Table 1).
Melanoma and bladder carcinoma cell lines showed high levels of normalized hTERT 
expression. In primary cell cultures, keratinocytes showed elevated normalized hTERT 
expression compared to skin fibroblasts. Peripheral blood mononuclear cells had moderate 
levels of normalized hTERT expression that were elevated to cancer cell line levels after in 
vitro mitogenic stimulation with phytohemagglutinin and IL-2. In normal tissues, normalized 
hTERT levels were relatively high in bone marrow, small intestine and testis, whereas lymph 
gland, stomach and colon expressed moderate levels. No hTERT expression was measured in 
lung, liver, pancreas, prostate, bladder, kidney, uterus and brain tissues. Our quantitative data 
match with semi-quantitative TRAP assay reports 1,6 without exception.
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Table 1. Mean expression levels ±SD of hTERT, rRNA and hTERT/rRNA ratio (normalized 
hTERT)for human cell lines,primary cultures and normal tissues.
Melanoma cell lines
hTERT” rRNAa Ratiob
1F6 7.63 ± 0.58 30.86 ± 1.90 24.72 ± 1.18
Mel57 4.87 ± 0.33 37.42 ± 4.13 13.18 ± 2.24
M14 5.58 ± 0.42 36.21 ± 5.63 15.71 ± 3.06
Bladder carcinoma cell lines
253J 4.70 ± 0.40 28.48 ± 4.88 16.93 ± 3.81
RT4 38.84 ± 5.38 34.64 ± 0.54 111.99 ± 13.8
SCaBER 11.40 ± 0.63 12.32 ± 0.44 92.74 ± 8.06
RT112 26.49 ± 3.67 30.33 ± 3.50 87.56 ± 9.62
Primary cell cultures
Fibroblasts 0.00 40.69 ± 2.13 0.00
Keratinocytes 0.33 ± 0.05 6.58 ± 0.50 5.07 ± 1.11
PBMCc 0.11 ± 0.00 20.25 ± 1.77 0.55 ± 0.05
PBMC +PHA/IL2d 15.24 ± 1.49 58.86 ± 1.70 25.94 ± 3.17
Normal tissues
Lymph gland 0.24 ± 0.03 24.30 ± 2.45 0.99 ± 0.11
Bone Marrow 0.17 ± 0.06 3.90 ± 0.23 4.42 ± 1.52
Lung 0.00 12.46 ± 1.22 0.00
Stomach 0.12 ± 0.04 30.07 ± 1.32 0.39 ± 0.15
Small intestine 0.98 ± 0.21 11.24 ± 1.17 8.84 ± 2.48
Colon 0.17 ± 0.01 12.24 ± 1.44 1.38 ± 0.20
Liver 0.00 38.74 ± 1.61 0.00
Pancreas 0.00 27.15 ± 1.90 0.00
Testis 1.75 ± 0.12 26.49 ± 1.44 6.64 ± 0.65
Prostate 0.00 39.11 ± 1.61 0.00
Bladder 0.00 21.21 ± 0.76 0.00
Kidney 0.00 25.75 ± 2.87 0.00
Uterus 0.00 22.97 ± 2.80 0.00
Brain 0.00 18.22 ± 1.17 0.00
aMean values of three separate measurements are expressed in nanogram of T24 bladder carcinoma cell line 
cDNA (cycle threshold values for all samples were transformed using a cDNA calibration curve (50 -  0.08 ng) 
of the bladder cell line T24).
bRatio = normalized hTERT expression = 100x (hTERT/rRNA) 
cPeripheral blood mononuclear cells 
dPhytohemagglutinin + Interleukine-2 stimulation
The real-time quantitative hTERT PCR assay has marked advantages: It can use small 
(partially degraded) fragments of RNA for quantification. It contains an endogenous control 
to correct for parameters affecting the assay, like RNA isolation efficiency, RNA degradation, 
or RT inhibitors. It has linearity over a 5-log range of input cDNA 4,5 and has a closed tube 
assay format, reducing assay time and the risk of PCR product carry over. Moreover, 
calculation of the quantitative PCR data is standardized by the use of a computer program, 
which automatically presents the cDNA input values for all samples after transformation of Ct 
values using the calibration curve, decreasing inter-assay and inter-laboratory variability.
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Our design of the quantitative hTERT assay will detect all known splicing variants of 
the hTERT gene, which are not yet functionally characterized and may possibly 
overestimate the functional hTERT expression. Nevertheless, our quantitative data 
corresponded very well with telomerase activity reports. Quantitative analysis of hTERT 
expression may therefore prove to be a promising tumor marker. Our results validate efforts to 
investigate the potential usefulness of hTERT quantification in tumor sections, especially
o
after laser-assisted cell picking .
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Real-time quantification of human telomerase reverse 
transcriptase mRNA in tumors and healthy tissues




Background: Expression of the hTERT gene, which codes for the catalytic subunit of 
telomerase, is associated with malignancy. We recently developed a real-time reverse 
transcription-PCR assay, based on TaqMan technology, for accurate and reproducible 
determination of hTERT mRNA expression (Lab Invest 1999;79:911-2). This method may be 
of interest for molecular tumor diagnostics in tissues and corresponding body fluids, 
washings, or brushes.
Methods: In this study, we measured hTERT expression in a subset of healthy tissues and 
tumors to select those tumor types with the best potential for quantification of hTERT in 
corresponding body fluids. To demonstate the use of the method in body fluids, we quantified 
hTERT expression in voided urine of patients with bladder cancer and controls.
Results: Real-time measurement of hTERT expression could discriminate between all healthy 
and malignant tissue samples from pancreas, lung, esophagus, and bladder, but not for colon 
tissues. Moreover, in five of nine (55%) urine samples, hTERT could be quantified. 
Conclusions: The present study demonstrates that accurate quantitative measurement of 
hTERT expression has high potential for discrimination between healthy and tumor cells in 
tissues and urine and supports future measurements in pancreatic fluid, bronchoalveolar 
lavage fluid, esophageal brushings, and urine or bladder washings.
Introduction
Body fluids, excrements, washings, or brushings (further summarized as bodily samples) are 
of interest in diagnostics because they can be obtained with minimally invasive or 
noninvasive techniques. For cancer diagnostics, mutant DNA derived from tumor cells has 
been found in feces 1, urine 2, sputum3, pancreatic fluid 4, bile 5, cerebrospinal fluid 6, and
7 8plasma/serum , and currently is being evaluated for use in early detection, prognosis, and 
follow-up studies of malignant processes. Unfortunately, not all tumors have readily 
detectable DNA aberrations such as K-ras mutations. In contrast, they may contain mutations 
scattered over the gene, microsatellite instability, or loss of heterozygosity, which are more 
difficult to detect, especially when a marked background of DNA from healthy tissue is 
present. As an alternative to the detection of DNA aberrations, quantification of gene 
expression in cells shed in bodily samples has been used as a tumor marker 9,1°.
Telomerase activity is the most general molecular marker for the identification of
human cancer and can be detected in 85% of all tumors, whereas most healthy tissues exhibit
11,12little or no telomerase expression . The enzyme needs at least two components to be
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functional: the RNA component, coded by the human telomerase RNA (hTR) gene and the 
human telomerase reverse transcriptase subunit (hTERT gene) which codes for the catalytic 
subunit of the enzyme 14-18. A method for the quantitative measurement of hTERT mRNA 
expression may be of interest for molecular diagnosis in tumors and corresponding bodily 
samples 19
We recently developed a method for the accurate measurement of hTERT expression,
20using real-time quantitative PCR 20. The method was applied to several cell lines, primary cell 
cultures, and healthy tissues, and quantification of hTERT expression showed good 
correlation with semiquantitative telomerase activity measurements. In the present study, we 
applied the novel method to several tumor and healthy tissue types to select those tumor types 
that have the best potential to be detected by hTERT measurements in corresponding bodily 




Frozen tissues (-80°C) from five different types of tumors (pancreas, lung, colon, esophagus, 
and bladder) were randomly selected from the tissue bank of the Department of Pathology 
(University Hospital Nijmegen). Samples of healthy tissue were obtained from autopsies with 
a postmortem delay of <4 h. For healthy bladder tissue, samples were enriched for urothelial 
cells by selective removal of nonepithelial tissue.
Percentage oftumor cells in tissue sections
Frozen 4-^m sections of tumor lesions were stained with hematoxylin and eosin. These 
sections were taken midway along the sections used for RNA isolation. A pathologist 
determined the percentage of tumor cells in the stained sections.
Urine
The second morning urine of nine patients with urothelial cell carcinoma was obtained before 
transurethral resection of the tumor. Urine was also obtained from four patients with 
nonmalignant bladder diseases; 50 mL of urine was centrifuged, and cell pellets were washed 





Total RNA from tissues was isolated by disruption of 20 frozen 20-^m sections in 1 mL of 
Trizol (Life Technologies), using a sterile pestle. After the manufacturer’s protocol was 
completed, RNA was further purified using the RNeasy kit (Qiagen), according to the RNA 
clean-up protocol, and eluted in 50 ^L of RNase-free destilled H2O (Life Technologies). The 
amount of RNA was measured spectrophotometrically. RNA from urine was isolated using 
Trizol with the addition of 2 ^g of poly(A) RNA as carrier. RNA was dissolved in 20 ^L of 
RNase-free H2O.
cDNA synthesis
Purified RNA (0.2-1.0 ^g) from tissue samples was supplemented with RNase-free H2O to a 
final volume of 10 ^L; 10 ^L of RNA isolated from the urine samples was used. All samples 
were denatured for 5 min at 90°C and cooled immediately on ice. Reverse transcription 
mixture (10 ^L) was added, containing first strand buffer (Life Technologies), 200 units of 
Moloney murine leukemia virus (Life Technologies), 20 units of RNasin (Promega), 10 
mmol/L dithiothreitol, 4.75 ^mol/L random hexamers and 600 ^mol/L deoxynucleotides. 
After the hexanucleotides were annealed for 10 min at 20°C, cDNA synthesis was performed 
for 45 min at 42°C, followed by an enzyme inactivation step for 5 min at 95°C. cDNA was 
stored at -20°C until use.
Real-time quantitative PCR
21The principle of the real-time quantitative PCR has been described by Heid et al. . For both 
hTERT and 18S ribosomal RNA (rRNA) expression measurements in tissue samples, 1 ^L of 
cDNA was used for amplification by the real-time quantitative PCR system (ABI Prism™ 
7700 Sequence Detection System; Perkin Elmer Applied Biosystems). For the measurement 
of rRNA and hTERT in urine, 1 ^L and 5 |iL were used, respectively. Reaction components 
(including TaqMan Universal Master Mix) and cycling conditions were identical to those 
described previously 20.
Emission spectra of all samples were collected every cycle during the last 30 s of the 
primer annealing/elongation step. The sytem was linked directly to a Power Macintosh 
7200/120 containing software to analyze data. For hTERT, calculation of the fluorescence 
threshold by the computer was at the default setting (10 SD above the mean base fluorescence 
from all samples, calculated from cycles 3-15). Because rRNA is expressed abundantly in
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tissue samples and already interferes with measurement of the base fluorescence during the 
early PCR cycles, the mean base fluorescence was calculated from PCR cycles 2-6. The 
number of PCR cycles to reach the fluorescence threshold was the cycle threshold (Ct). The 
Ct value for each sample was proportional to the log of the initial amount of input cDNA. For 
the calibration curves for both hTERT and rRNA, we used cDNA from a T24 bladder 
carcinoma cell line to make the transformations from Ct values to nanograms of cDNA, as 
described previously 20. The rRNA expression was used to normalize hTERT expression for 




With the development of a TaqMan Universal Master Mix (Perkin Elmer) to which only
primers, probe, and sample must be added, PCR efficiencies became highly reproducible,
20producing similar slopes for the calibration curves between experiments . In the present 
experiment, the functions of the calibration curves were: Ct = -3.72 log [hTERT] + 32.84; and
Ct = -3.60 log [rRNA] + 12.94; slopes did not differ significantly from the previous
20experiments . However, the height of the curves (especially for rRNA) varied between 
experiments, partly because of sample dilution in the previous experiments.
As an additional control for reproducibility between experiments, hTERT and rRNA 
expression were measured in the cDNA of two calibrators: the bladder carcinoma cell lines 
RT4 and SCaBER. The normalized hTERT values were 122.03 for RT4 and 89.53 for
SCaBER (Table 1) and were not significantly different from previous measurements: 111.99
20± 13.8 and 92.74 ± 8.06, respectively . Because the method is very reproducible, normalized 
hTERT values between experiments could be compared directly.
hTERT in tumors and healthy tissues
Normalized hTERT expression was measured in five different tumor types and compared 
with the corresponding healthy tissues (Table 1). Healthy pancreas tissue (n=3) did not 
express hTERT above the detection limit, whereas all three tumors did. Sample PT1 had low 
hTERT expression, which is partly attributable to the relatively low amount of tumor tissue 
(30%) in the sample.
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Table 1. Expression level o/hTERT, rRNA and normalized hTERT in tumors, corresponding 
normal tissues and cell lines.
Cells or tissue Code Tumor/Normal hTERT“ rRNA“ Normalized % Tumor
type hTERT in sample6
Pancreas PN1 Healthy tissue 0.00 31.62 0.00
PN2 Healthy tissue 0.00 18.72 0.00
PN3 Healthy tissue 0.00 28.36 0.00
PT1 Adenocarcinoma 0.08 21.27 0.36 30
PT2 Adenocarcinoma 1.79 29.29 6.11 70
PT3 Neuroendocrine tumor 0.62 22.53 2.77 90
Lung LN1 Healthy tissue 0.11 20.60 0.54
LN2 Healthy tissue 0.09 16.79 0.51
LN3 Healthy tissue 0.08 22.53 0.34
LT1 Large cell carcinoma 0.12 23.56 0.53 40
LT2 Adenocarcinoma 5.80 28.91 20.1 40
LT3 Adenocarcinoma 0.62 25.94 2.41 60
LT4 Adonocarcinoma 1.40 21.27 6.57 60
LT5 Non-differentiated carcinoma 0.85 14.58 5.84 40
Colon CN1 Healthy tissue 1.90 29.10 6.54
CN2 Healthy tissue 1.03 13.77 7.44
CT1 Adenocarcinoma 0.59 30.05 1.95 60
CT2 Adenocarcinoma 0.75 21.54 3.49 20
CT3 Adenocarcinoma 5.80 29.29 19.8 80
CT4 Adenocarcinoma 0.85 24.80 3.43 40
CT5 Adenocarcinoma 1.05 21.27 4.94 40
Esophagus ON1 Healthy squamous epithelium 0.12 23.56 0.50
ON2 Healthy squamous epithelium 0.00 8.80 0.00
ON3 Healthy squamous epithelium 0.25 19.57 1.26
OT1 Adenocarcinoma 0.75 22.10 3.40 20
OT2 Adenocarcinoma 1.68 19.70 8.54 50
OT3 Adenocarcinoma 0.91 15.25 5.94 30
OT4 Adenocarcinoma 1.49 20.21 7.35 15
OT5 Adenocarcinoma 1.49 22.97 6.47 10
OT6 Adenocarcinoma 2.29 21.68 10.57 10
Bladder BN1 Healthy epithelium 0.00 29.85 0.00
BN2 Healthy epithelium 0.00 29.29 0.00
BN3 Healthy epithelium 0.00 16.79 0.00
BT1 Carcinoma 0.23 16.90 1.37 80
BT2 Carcinoma 2.09 14.12 14.80 50
BT3 Carcinoma 0.19 10.53 1.80 70
BT4 Carcinoma 1.82 17.90 10.17 70
BT5 Carcinoma 3.24 12.83 25.25 75
BT6 Carcinoma 1.73 23.41 7.41 50
Cell Lines RT4 Bladder carcinoma cell line 37.61 30.82 122.03
SCaBER Bladder carcinoma cell line 12.65 14.13 89.53
a Cycle threshold (Ct) values for all samples were transformed to nanograms of cDNA by use of a calibration 
curve for the T24 cell line. Values are therefore expressed in nanograms of T24 bladder carcinoma cell line 
cDNA. Functions of the calibration curves were: Ct(hTERT) = -3.72 log[hTERT] + 32.84 and Ct(rRNA) = -3.60 
log[rRNA] + 12.94.
b Normalized hTERT = 100x (hTERT/rRNA)
‘ Percentage of tumor cells in sample was scored by a pathologist in frozen tumor sections stained with 
hematoxylin and eosin.
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All three samples of healthy lung tissue contained low hTERT expression; whereas 
expression in four of five lung tumors was at least fivefold higher. When sample LT1 was 
corrected for tumor percentage (0.53 x 2.5), the expression was also higher than in healthy 
tissues. Both samples of healthy colonic tissues expressed high concentrations of hTERT 
within the range of the colorectal adenocarcinomas. Two of three samples of healthy 
esophagus tissues did express hTERT. However, all six esophageal carcinomas expressed 
higher concentrations, especially considering the low precentage of tumor tissue in most 
samples. Three samples of healthy bladder wall tissue did not express hTERT, whereas all six 
bladder carcinomas expressed hTERT, with normalized values ranging from 1.37 to 25.3.
hTERT in urine
Normalized hTERT expression was measured in nine urine samples of patients with tumors of 
various stages and grades. hTERT expression was also measured in urine from four donors 
with nonmalignant bladder diseases as specificity controls (Table 2). In the urine of five 
patients (55%), hTERT could be quantified. In the urine of four patients and in the specificity 
controls, no hTERT was detected. The urine of both patients with a carcinoma in situ and a 
superficial tumor had much higher normalized hTERT expression than patients with solely a 
superficial tumor.






U1 Ta 1 0.00
U2 Ta 1 0.00
U3 Ta 2 2.04
U4 Ta 2 0.00
U5 Ta 2 2.75
U6 T1 2 1.51
U7 T1 3 0.00
U8 T1/CIS‘ 3 35.16
U9 T1/CIS‘ 3 10.77
U10 -  U13 No malignancy 0.00
a TNM classification 43 
b WHO grading system 44 
c Carcinoma in situ.
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Telom erase activity is associated w ith the acquisition o f  m alignancy and m ay have potential
22as a b iom arker for the early detection o f  cancer . It is o f  im portance that the detection o f 
cancer is achievable in specim ens obtained by relatively noninvasive procedures. For 
exam ple, telom erase activity m easured w ith the telom eric repeat am plification protocol
23 24-28 29(TRA P)23 has been detected in urine or b ladder w ashings 24-28, bronchoalveolar lavage fluid 29,
30 31pancreatic ju ice  , and colonic lum inal w ashings . B ecause the TRAP needs the fuctional 
ribonucleoprotein, the presence o f  protein activity inhibitors, proteases, or R N ases in an 
aggressive m edium  m ay com plicate detection and subsequently low er sensitivity.
W ith the cloning o f  both genes coding for the R N A  (hTR) and protein com ponent 
(hTERT) o f  telom erase, it soon becam e clear that only the expression o f  hTER T w as closely
18,32correlated w ith telom erase activity ’ . Screening o f  hTER T expression using N orthern 
blotting, R T -PC R  and in situ hybridization in various tum ors and healthy tissues confirm ed
33-35these initial findings 33-35. H ow ever, an interesting exception to  the relationship betw een 
hTER T expression and telom erase activity w as found in W ilm s tum or, w here only hTERT 
expression but not telom erase activity significantly correlated w ith recurrence 36. M oreover, 
several splicing variants o f  hTER T m R N A  are found w ith still unknow n functions 16. In 
addition to  tissues, the presence o f  hTER T m R N A  w as tested in bodily  samples, bu t w ithout
37,38accurate quantitative m ethods .
W e recently developed an assay for the accurate quantification o f  hTER T expression 20. 
A n advantage o f  this assay com pared w ith the TRAP assay is that it needs only a 144-base 
fragm ent o f  hTER T m RNA , m aking the assay less sensitive to R N ase activity and insensitive 
to  proteases and protein inhibitors. M oreover, the inclusion o f  an endogenous control (rRNA) 
in the assay norm alizes the hTER T expression for cD N A  input and assay affectors. The rea l­
tim e quantitative PC R  m ethod is very reproducible betw een experim ents, w ith equal slopes o f 
the calibration curves but different heights. I f  the PC R  efficiency rem ains constant in 
successive experim ents, the m easurem ent o f  a calibration curve will becom e superfluous and 
can be replaced by a calibrator that corrects solely for height differences betw een 
experim ents.
For our analyses, w e m ade a selection o f  tum or types o f  w hich cells m ay be found in 
bodily samples. All tum ors in our study expressed hTERT. H ealthy panceas and bladder 
tissues did not express hTERT. The results for bladder tissues are in agreem ent w ith the 
results obtained by Ito et a l.34, w ho detected hTER T expression in only 3 o f  18 healthy
Discussion
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bladder tissue samples but in 30 of 33 urothelial cancers by use of RT-PCR. Possibly, 
quantitative measurement of hTERT expression in these tissues could have discriminated 
these three positive healthy bladder tissue samples from the tumors when a cutoff 
concentration was determined. This advantage of real-time RT-PCR was shown by Hisatomi
39et al. , who determined a cutoff concentration using real-time quantification of hTERT 
expression to differentiate between malignant and benign hepatocellular tissues.
In healthy lung, very low background hTERT expression was detected in all samples. 
Although in a recent study no hTERT mRNA was found in individual cells from healthy lung
35by in situ hybridization , our results are not in conflict with these results because PCR 
detection is more sensitive. Moreover, low hTERT expression in lung tissue can also be 
caused by the presence of (inflammatory) leukocytes 40.
In healthy esophagus tissue, hTERT expression has been found by us and others and is
35predominantly localized to the basal cell layers of the columnar epithelium . These basal 
cells are not likely to be removed during superficial esophageal brushings and therefore are 
not expected to interfere with the detection of neoplasia (in contrast to biopsies). In patients 
with progressive Barretts esophagus, hTERT quantification in brushings may be of interest for 
the detection of onset of malignancy 41.
Both samples of healthy colonic tissues expressed high concentrations of hTERT. This is 
in agreement with other reports in which hTERT expression was detected in colonic crypt 
epithelial cells 35,42. Although no hTERT expresssion was present in cells at the top of the 
crypts, which are predominantly shed into the lumen of the colon, the ubiquity of 
inflammatory lymphocytes expressing high concentrations of hTERT may interfere with 
hTERT quantification in feces or colonic effluent samples 35,40.
Our results show that real-time measurement of hTERT expression discriminates between 
healthy and malignant tissues for pancreatic, lung, esophageal and bladder tissues. This 
discrimination would have been even more distinct if the percentage of tumor cells was higher 
in the selected tissues. In future studies, using higher numbers of healthy tissue samples and 
neoplasms with high percentages of tumor cells, accurate cutoff concentrations may be chosen 
to determine the sensitivity and specificity for each type of tissue. Even for discrimination 
between healthy colonic and tumor tissues, a cutoff may be determined to increase specificity, 
although sensitivity will probably be compromised.
Overall, the different hTERT expression ranges between tumor tissues and healthy tissues 
suggested promising applications for the detection of tumor cells in pancreatic fluid, 
bronchoalveolar washings, esophageal brushings, and urine or bladder washings. To
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demonstrate this potential use, we collected the voided urine of nine patients scheduled for 
transurethral resection of a superficial bladder carcinoma and quantified hTERT after RNA 
isolation. In five urine samples, hTERT could be quantified, with the most aggressive tumors 
(carcinoma in situ) expressing the highest concentrations of hTERT, whereas all control 
urines were negative. It would be interesting to determine whether the quantification of 
hTERT expression in the urine would be useful in the diagnosis and follow-up of patients 
with bladder cancer.
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Chapter 8
Quantitative measurement of telomerase reverse transcriptase 
(hTERT) mRNA in urothelial cell carcinomas




Telomerase reverse transcriptase (hTERT) messenger RNA has been detected in 95% of 
bladder tumors using RT-PCR. In this study, we quantified the expression of hTERT in 35 
bladder urothelial cell carcinomas and in 6 normal bladder epithelia using a real-time 
quantitative PCR assay. hTERT expression was detected in all 35 urothelial cell carcinomas 
of varying grade and stage, but not in normal tissue samples. An increase in both pathological 
grade and clinical stage as prognostic parameters correlated with increased hTERT 
expression. Using different cutoff values for grades and stages, normalized hTERT expression 
values could discriminate among low, medium, and high grade tumors and between 
superficial and muscle-invasive tumors. We conclude that standardized real-time 
measurement of hTERT expression can be used for early tumor detection and may be used for 
determination of prognosis in urothelial cell carcinomas.
Introduction
About 95% of all bladder carcinomas are urothelial cell carcinomas (UCC). At initial 
presentation, 75-85% are superficial tumors limited to the mucosa (Ta) or the submucosa 
(T1), whereas the remaining are muscle invasive (T2-T4). Although radical cystectomy is 
indicated for muscle-invasive tumors, the superficial papillary tumors are treated more 
conservatively with transurethral resection. However, in 70% of these patients, multiple
superficial recurrences will occur with 10-20% progression to muscle-invasive or metastatic
1 2disease , . In these superficial tumors, early diagnosis together with accurate prediction of 
progression would enable the urologist to adapt therapeutic strategy at a time when the tumor 
is truly curable.
Prognosis in bladder cancer is clearly related to microscopic arrangement of the tumor 
(grade) and degree of invasion (stage). These pathological changes and their clinical 
manifestations are preceded by molecular and biochemical alterations, which may offer early 
detection of progression to malignancy. Gross molecular alterations like DNA ploidy and 
several chromosomal abnormalities have been related to aggressive disease and progression of 
UCC (reviewed in refs. 2-4). Also, increased expression of p53 and epidermal growth factor 
receptor and decreased expression of E-cadherin have been identified as independent factors
3 5for prognosis 3-5. Unfortunately, the sensitivity of these individual markers is still too low to 
be introduced in clinical practice, indicating the need for new markers.
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Telomerase activation is a critical step in cell immortalization. It is required in the 
advancement of the neoplasm to malignancy and has been detected in approximately 95% of 
UCC 6-8. Although estimation of telomerase activity seems useful for early detection, the 
correlation between telomerase activity and prognostic factors like grade and stage is not 
clear, illustrated by conflicting reports in the literature 6,7
Recently, the gene coding for the catalytic subunit of telomerase (hTERT) was 
identified 9-13. The close relationship between hTERT expression and telomerase activity 
suggests that quantification of the expression of the hTERT gene may be used as an 
alternative to telomerase activity measurement 14-16. In a recent study on Wilms’ tumors, only 
hTERT mRNA expression, not telomerase activity, was found to correlate with tumor
17recurrence . The authors attributed this disparity in findings to limitations of the TRAP 
assay. Their assay for semi-quantitative determination of hTERT expression was more 
accurate than telomerase activity measurement, consequently resulting in a distinct correlation 
with prognosis.
We recently developed an assay for the accurate quantification of hTERT mRNA
18using real-time quantitative PCR . In order to investigate whether this assay could improve 
staging and grading of UCC, we applied this assay to 35 UCC and 6 normal urothelia.
Materials and Methods
Tissue samples.
Tissue samples were obtained by cystectomy or transurethral resection from 35 patients with 
bladder cancer at the Canisius Wilhelmina Hospital (Nijmegen, The Netherlands) and the 
University Hospital Nijmegen (The Netherlands). Clinico-pathological details were evaluated
using the WHO criteria for determination of grade 19 and TNM classification for
20determination of stage . Six normal bladder tissues were obtained from patients who 
underwent surgery for other diseases. All samples were frozen in liquid nitrogen and stored at 
-80°C until use.
RNA extraction
Frozen tumor and normal tissue samples were step sectioned with hematoxylin and eosin 
staining evaluation at regular intervals so that samples contained >50% tumor cells or >75% 
normal urothelial cells, respectively. Total RNA was isolated by disruption of 10 frozen 20 
^m sections in 1 ml TRIZOL (Life Technologies, Breda, The Netherlands) using a sterile
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pestle. After completing the manufacturer’s protocol for TRIZOL, RNA quantity was 
measured spectrophotometrically.
cDNA synthesis
Purified RNA (0.2-1.0 ^g) was added to RNase-free water to a final volume of 10 ^l, 
denatured for 5 min. at 90°C and immediately cooled on ice. Ten microliters of RT mix was 
added containing first strand buffer (Life technologies), 200 U Moloney murine leukemia 
virus (MMLV)(Life Technologies), 20 U RNasin (Promega, Madison, WI), 10 mM 
dithiothreitol (DTT), 4.75 ^M random hexamers, and 600 ^M deoxynucleotides. After 
annealing of the hexanucleotides for 10 min. at 20°C, cDNA synthesis was performed for 45 
min. at 42°C followed by an enzyme inactivation step for 5 min. at 95°C. cDNA was stored at 
-20°C until use.
Real-time quantitative PCR
21The principle of the real-time quantitative PCR has been described by Heid et al. . The level
of 18S rRNA (rRNA) expression was quantitatively measured to normalize hTERT
expression for sample-to-sample differences in RNA input, RNA quality, and RT efficiency.
For both hTERT and rRNA expression measurements, 10-50 ng of reverse-transcribed RNA
(1 ^l cDNA) was used for amplification by the real-time quantitative PCR system (ABI Prism
7700 Sequence Detection System, Perkin Elmer Applied Biosystems, Foster City, CA).
Reaction components, including TaqMan Universal Master Mix, and cycling parameters were
18identical as described before .
Emission spectra of all samples were collected every cycle during the last 30 sec. of 
the primer annealing/elongation step. The sytem was directly linked to a Power Macintosh 
7200/120 containing software to analyze data. For hTERT, calculation of the fluorescence 
threshold by the computer was at default setting (10 times the standard deviation above the 
mean base fluorescence from all samples, calculated from cycles 3 to 15). Because rRNA is 
abundantly expressed in our samples and may interfere with measurement of the base 
fluorescence during the early PCR cycles, the mean base fluorescence was set to be calculated 
from PCR cycles 2 to 6.
The number of PCR cycles to reach the fluorescence threshold is the cycle threshold 
(Ct). The Ct value for each sample is proportional to the log of the initial amount of input 
cDNA. The cDNA from a T24 bladder carcinoma cell line (50-0.08 ng) was used as the 
calibration curve for both hTERT and rRNA measurements. The Ct values of all samples
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were transformed to nanograms of T24 cDNA values (for both hTERT and rRNA) using the 
calibration curves in the same experiment. The ratio (in percent) between nanograms of 
hTERT (expressed in T24 cDNA) and rRNA (expressed in T24 cDNA) represents the
normalized hTERT expression for each sample and can be compared directly with that of
18other samples .
Statistical Analysis
Analysis of variance was used to test statistical differences in normalized hTERT, after 
ranking, between stage and grade classes.
Results
We quantified the expression of the hTERT gene in 35 UCC and 6 normal urothelial tissues.
hTERT expression was standardized for sample-to-sample variations using the expression of
18rRNA as normalization . Consequently, hTERT expression was presented as normalized 
hTERT (Table 1). All 35 UCC had normalized hTERT at different levels but none of the 6 
histologically normal bladder epithelia expressed hTERT. Therefore, both sensitivity and 
specificity were 100%.
In addition to the distinct differences between normal bladder tissues and tumors, the 
relationship between histo-pathological parameters of bladder tumors and normalized hTERT 
was studied (Table 2). hTERT expression in grade I tumors significantly differed from grade 
III tumors (P < 0.001) but not from grade II tumors (P = 0.109). Also, expression in grade II 
tumors differed from grade III tumors (P = 0.001). For stage, hTERT values were similar for 
Ta and T1 tumors and for T2 and T3 tumors in our study. Therefore, stage groups were 
analyzed either as superficial (Ta/T1) tumors or as muscle-invasive (T2/T3) tumors. As 
shown in table 2, superficial tumors significantly differed in hTERT expression from muscle- 
invasive tumors (P = 0.02).
Because of these significant differences in normalized hTERT expression between 
superficial and invasive tumors and among high (III), medium (II), and low grade (I) tumors, 
we determined optimal cutoff points between stage and grade classes, using equal 
probabilities for misclassification for two adjacent classes. Normalized hTERT cutoff levels 
of 2.35 and 6.80 were determined to differentiate between grades. Typically, in the <2.35 
class, only grade I and II tumors were present; in the >6.80 class only grade II and III tumors 
were found in the (Table 3). In between 2.35 and 6.80 all grades were found.
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Table 1. Normalized hTERT expression in UCC and normal urothelium.
Sample
Pathological Expression“
Stage” Grade” hTERT rRNA Normalized
hTERT
1 Ta I 0.78 37.17 2.11
2 Ta I 0.73 30.67 2.38
3 Ta I 0.18 21.88 0.85
4 Ta I 1.63 32.56 5.02
5 Ta I 0.07 14.23 0.47
6 Ta II 0.77 33.65 2.28
7 Ta II 3.27 26.87 12.16
8 Ta II 0.16 24.98 0.66
9 Ta II 0.03 36.44 0.08
10 Ta III 2.92 33.43 16.37
11 T1 I 0.27 29.09 0.92
12 T1 II 0.28 23.07 1.22
13 T1 II 0.44 23.23 1.91
14 T1 II 5.47 27.05 20.23
15 T1 II 8.19 34.79 23.53
16 T1 II 0.83 16.14 5.17
17 T1 II 1.03 21.03 4.88
18 T2 II 0.46 19.30 2.41
19 T2 II 1.57 38.16 4.12
20 T2 III 11.07 30.67 36.10
21 T2 III 2.93 18.67 15.72
22 T2 III 0.64 21.45 3.00
23 T2 III 8.13 28.52 28.52
24 T2 III 0.42 13.50 3.15
25 T2 III 0.87 17.13 5.05
26 T2 III 3.23 33.43 9.65
27 T2 III 2.90 21.03 13.78
28 T2 III 8.94 13.68 65.37
29 T2 III 3.11 27.41 11.33
30 T3 III 6.25 37.17 16.80
31 T3 III 8.23 27.41 30.06
32 T3 III 4.62 33.88 13.63
33 T3 III 2.92 34.10 8.55
34 T3 III 2.69 41.87 6.42
35 T3 III 6.28 34.33 18.31
N1 Normal Urothelium 0.00 30.05 0.00
N2 Normal Urothelium 0.00 21.16 0.00
N2 Normal Urothelium 0.00 14.78 0.00
N4 Normal Urothelium 0.00 23.41 0.00
N5 Normal Urothelium 0.00 20.16 0.00
N6 Normal Urothelium 0.00 29.67 0.00
a TNM classification 19. 
b WHO grading system 20.
c Ct values of for all samples were transformed to nanograms of total cDNA by use of calibration curves of T24 
bladder carcinoma cell line (0.08-50 ng cDNA). Presented values for hTERT and rRNA are therefore expressed 
(after transformation) in nanograms of T24 cDNA. Functions of the calibration curves were: f(Ct hTERT) = -3.659 
log [hTERT] + 32.911 (r2 = 0.999) and f(Ct rRNA) = -3.478 log [rRNA] + 15.801 (r2 = 0.998). 
d Normalized hTERT = 100x (hTERT/ rRNA).
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With regard to stage, the cutoff point between superficial and invasive tumors was 
7.40. Of the 16 tumors with high normalized hTERT (>7.40), 75% were invasive. In the low 
hTERT class (<7.40), 13 of 19 tumors (68%) were superficial.
To examine whether the quantification of hTERT expression had additional value to 
clinico-pathological parameters, the clinical course of all patients with superficial tumors was 
analyzed. Of the 17 cases with Ta/T1 tumor stage, two showed progressive disease during 
follow-up. Both cases had high normalized hTERT expression. In one patient, the tumor 
(sample 10, Table 1) progressed to an invasive (T2) tumor within 8 months and the patient 
died of metastatic disease after 21 months. In the second patient, the tumor (sample 7, Table 
1) recurred very frequently, e.g., 2, 6, 8, and 12 months after transurethral resection of the first 
tumor. Because this tumor was at high risk for progression, the urologist decided to perform 
radical cystectomy and the patient remained disease-free in the follow-up. In 11 of the 15 
remaining patients recurrences occurred, but there was no progression during at least 2 years 
of follow-up.
Table 2. Mean normalized hTERT expression ±  standard error for different stages and 
grades o f UCC and normal tissues.





2.O ± 4.9 






5.9 ± 3.O 
16.2 ± 2.9 L
J d
Normal O.O ± O.O
a See Table 1
b Difference between Grade I and III (P < 0.001).
c Difference between Grade II and III (P = 0.001).
d Difference between superficial and muscle invasive tumors (P = 0.02).
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<2.35 4 5 0
2.35 - 6.80 b 2 4 4
>6.80 0 3 13
Stage
Normalized hTERTa Superficial Invasive
<7.40 b 13 6
>7.40 4 12
a See Table 1
b Cutoff points were determined using equal probabilities of misclassification for two adjacent classes of either 
grade or stage.
Discussion
Expression o f  the hTERT gene is the rate-limiting determinant o f  telomerase activity and may 
be used as an alternative tumor marker 12-16. The use o f  real-time PCR for accurate 
quantification o f  hTERT expression has marked advantages to semi-quantitative telomerase
22 23activity measurements using the TRAP ’ . Although the TRAP has internal controls to
detect PCR inhibitors and spurious telomerase activity, it cannot control for R N A template
degradation or enzyme inactivation with time. In contrast, the real-time hTERT assay contains
an endogenous control to correct for various parameters affecting the assay like RNA
18degradation, isolation efficiency and RT inhibitors . It has a closed tube amplification and 
amplicon detection format, reducing time o f  analysis and risk o f  PCR product contamination. 
Detection is standardized by the use o f  a computer, reducing inter- and intra-observer 
variability. Because the real-time assay only needs a 144-bp fragment o f  the hTERT mRNA, 
it is probably less sensitive than telomerase to the presence o f  RNases. Moreover, it is 
insensitive to proteinases and protein inhibitors. The real-time PCR has linearity o f  
quantification over a 5-log range o f  cD N A  input, eliminating the need for various input 
quantities required for the TRAP.
With this novel assay, w e analyzed the gene expression o f  the catalytic subunit o f  
telomerase (hTERT) in 35 UCC, differing in stage and grade, and in 6 normal bladder 
urothelia. All tumors expressed hTERT mRNA, whereas normal tissues were all negative. 
Results were in concordance with a previous study in which hTERT expression was detected
24in 17 o f  18 urothelial cancers and in only 3 o f  18 normal tissues . Our sensitive and specific
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results also corroborate the potential for early bladder tumor detection by analyzing the
25presence o f  hTERT m R N A  in urine . E specia lly  in an aggressive m edium  like urine, the 
detection o f  hTERT m R N A  m ay be m ore sensitive than telom erase activity m easurem ent due 
to its insensitivity to proteases or protein inhibitors.
In UCC , a relationship betw een telom erase activity and prognosis (defined by stage and
6 7 26 28grade) w as found in one study , but not in m ost other studies , - . E ven though the number 
o f  tumors w as lim ited in our study, significant d ifferences w ere found betw een  grade I and III 
tumors (P  <  0 .001) and grade II and III tumors (P  =  0 .001), but not betw een  grade I and II 
tumors (P  =  0 .109). A lso , hTERT expression betw een superficial (Ta/T1) and invasive  
(T 2/T 3) bladder tumors differed significantly (P  =  0.02). T hese data suggest that m alignant 
progression is associated w ith the expression level o f  the hTERT gene.
N ext, w e  determined cu to ff points betw een adjacent stage and grade classes to enable 
classification  o f  tumors based on their norm alized hTERT value. Increase in norm alized  
hTERT, defined by cu to ff points for classes, clearly correlated w ith increase in both grade and 
stage. H ow ever, the demarcation betw een norm alized hTERT values in relation w ith stage 
and grade w as not absolute. This m ay reflect know n interobserver variability in grading and
29-32staging by different pathologists or even  the sam e person . Another possib ility  is that 
deviant hTERT expression m ay identify aggressive tumors not detected by clin ico- 
pathological parameters. This w ould  be especially  useful for the identification o f  10-20%  o f
33the superficial tumors that w ill progress during fo llow -up  . Interestingly, tw o  patients w ith  
superficial tumors and high hTERT expression show ed either very frequent recurrences or 
progressive disease. H ow ever, tw o other superficial tumors w ith  high hTERT expression  
(Table 1, sam ples 14 and 15) did not progress. This m ay be explained by the m ore radical 
treatment (bacillus Calm ette-G uerin and m itom icin) that both patients received  after resection  
o f  the tumor. A lthough these results are prom ising, a more extensive study w ill be necessary  
to identify hTERT expression as an independent progression marker that could im prove
17therapeutic strategies as w as indicated in W ilm s’ tumors .
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Summary
M ost superficial urothelial cell carcinom as w ill recur after surgical resection and 10% o f  these  
recurrences progress to high grade and m uscle-invasive disease. Early detection o f  these  
recurrences together w ith  prediction o f  progression w ill im prove clinical managem ent. In this 
study w e  com pared the diagnostic and prognostic value o f  telom erase and hTERT m R N A  in 
urine and bladder w ash ings o f  42 patients w ith  recurrent urothelial cell carcinom as. 
T elom erase activity w as measured by the tel om  eric repeat am plification protocol (TRA P), 
whereas hTERT expresssion  w as quantified using real-tim e quantitative PCR. Sensitivity in 
urine w as lo w  for both telom erase (29% ) and hTERT expression (24% ). The sensitivity in 
bladder w ash ings w as higher; 56% for telom erase and 50% for hTERT m R N A , but still too  
lo w  to replace cystoscopy as a diagnostic tool. In contrast to the TRAP, accurate 
quantification o f  hTERT expression in bladder w ashings could discrim inate betw een  the 
presence o f  high grade tumors (including carcinom a in situ) and low  grade tumors, w hen  
using a hTERT cu to ff value. Therefore, as a supplem ent to cystoscopy, quantification o f  
hTERT expression in bladder w ashings m ay identify aggressive recurrent tumors w ith  high  
progression risk.
Introduction
In western countries, bladder cancer is the fourth m ost com m on cancer in m en and ninth in 
w om en  1. Urothelial cell carcinom as (U C C ) represent 95%  o f  all h istological types o f  bladder 
cancer. A t clinical presentation, 75-85%  o f  U C C  are superficial (Ta/T1) and o f  lo w  (I) or 
m edium  (II) h istologic grade . Typically, after transurethral resection o f  the tumor 
approxim ately 70%  w ill recur w ithin 5 years. M ost o f  these superficial tumors recur w ith the 
sam e stage and grade and their prognosis is good. H ow ever, a m inority (10-20% ) o f  the 
tumors w ill progress to m uscle-invasive disease. Early detection o f  recurrences together w ith  
prediction o f  progression w ould  enable the urologist to determine individual therapy to reduce 
recurrences and prevent or delay tumor progression.
A s a diagnostic tool, for the early detection o f  recurrent disease, cystoscopy is 
considered the gold-standard. Unfortunately, the procedure is both invasive and costly. A s a 
noninvasive alternative, cy to logy  in voided  urine can be used  to identify the presence o f  
tumor cells. H ow ever, urine cyto logy  as a diagnostic tool has poor sensitivity, particularly in 
lo w  grade lesions w here the m orphological features o f  shedded neoplastic cells are often  
indistinguishable from normal urothelial ce lls 3,4. Thus, the sensitivity o f  urine cyto logy  is 
dependent on the expertice o f  the cytopathologist, resulting in observer variability 5.
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Irrespective o f  the disadvantages as a diagnostic tool, cy to logy  is often used  as a tool 
to supplem ent cystoscopy for the prediction o f  progression. After all, cyto logy  can detect the 
presence o f  ce lls derived from carcinom a in situ  (C IS) or small high-grade tumors, both  
m issed  frequently w ith  cystoscopy 6,7. The presence o f  these synchronous and aggressive  
lesions greatly elevate progression risk in recurrent d isease 1. A s a supplem ent to cystoscopy, 
cyto logy  is usually performed in bladder w ash ing sam ples, w h ich  is m ore sensitive than
3,7cyto logy  in urine 3,7. These w ashings can be obtained easily  during cystoscopy. H ow ever, 
repeated bladder m anipulations or urinary tract infections m ay com plicate the cytological 
diagnosis by causing m orphological changes in exfoliated  cells . Therefore, cy to logy  also has 
observer variability w hen used  as a supplem ent to cystoscopy.
B ecause m orphological changes in tumor cells coincide w ith  m olecular and 
biochem ical alterations, attempts w ere m ade to im prove urine/w ash sensitivity and 
reproducibility by u se o f  im m unochem ical or m olecular tumor markers 5. One o f  the m ost
9 12prom ising markers, telom erase activity, w as detected in 95%  o f  bladder tumors " by use o f  
the telom eric repeat am plification protocol (TR A P) 13,14 .
W e have recently developed  a m ethod for the accurate quantification o f  the expression  
o f  the telom erase reverse transcriptase (hTERT) gene, coding for the catalytic subunit o f  
telom erase 15. In a subsequent study w e  show ed that all urothelial cell carcinom as expressed  
hTERT, w hereas healthy bladder tissues had no expression 16. Increase in hTERT expression  
in tumors correlated w ith  increase in both stage and grade. This suggested that hTERT m R N A  
expression w as not only a diagnostic marker, but m ay also be a prognostic marker in U C C  16.
The present study has tw o aims. First, to com pare TRAP and hTERT expression  
m easurem ent w ith  cystoscopy for the detection o f  recurrent U C C  in urine. Second, to explore  
the supplemental value o f  cytology, TRAP, or hTERT expression to cystoscopy as a 
prognostic tool in bladder w ash ings for the detection o f  potential aggressive tumors.
Patients and Methods
Urine and bladder washing sam ples
Fourty-tw o patients, under suspicion o f  recurrent U C C  based on cystoscopic exam ination, 
w ere asked to participate in the study. D uring cystoscopy, a bladder w ash ing w as obtained  
from 40 o f  42  patients, and w as sent to the Departm ent o f  Pathology for cytological 
exam ination. B efore transurethral resection o f  the tumor, another bladder w ash ing (100  m l) 
and the second m orning urine (100 m l) w ere collected  and im m ediately cooled  on ice. Urine 
and w ash ing w ere divided in tw o equal parts (one part for TRAP m easurem ent and one for
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hTERT m R N A  quantification), centrifuged for 10 m inutes at 800 xg, and the pellet w as 
w ashed tw o tim es w ith  ice-co ld  phosphate-buffered saline (PB S). The cell pellet o f  the urine 
sam ple w as snap-frozen in liquid nitrogen and subsequently stored at -8 0 °C . The cell pellet 
from the bladder w ash ing w as resuspended in ice-co ld  PB S, containing 1.5% fetal ca lf serum  
(FC S) and urothelial ce lls  w ere selected  using 30 ^l o f  m agnetic beads (3x10  particles) 
coated w ith  an antibody (Ber-EP4) against epithelial ce lls  (D ynal, O slo, N orw ay). After 
incubation (4°C , 30 m inutes), bead-bound urothelial ce lls  w ere w ashed three tim es w ith  PBS  
containing 1.5% FCS. The beads w ere snap frozen in liquid nitrogen and stored at -80°C . A s  
specificity  controls, bladder w ash ings from 14 catheterized tum or-free patients w ere  
collected , processed and stored.
A ll sam ples w ere coded prior to analysis for TRAP and hTERT m R N A  expression. 
A fter analysis, the code w as broken and results w ere com pared w ith (cyto)pathological 
reports.
Telomeric R epeat Am plification P rotocol (TRAP)
The TRAP w as performed on stored cell pellets from urine and bladder w ashing sam ples, 
fo llow in g  the instructions o f  the T R A Peze K it (Intergen, Purchase, N Y ). A fter addition o f  
lysis  buffer, the protein content o f  the lysate w as determined by use o f  C oom assie Brilliant 
B lue (BioRad, M ünchen, Germany). A  total protein input o f  0 .2, 2 .0 , and 6 .0  ^g w as used in 
the TRAP. A s a control for spurious telom erase activity, part o f  the lysate w as heat- 
inactivated at 95°C  for 10 minutes. A  control for the presence o f  PC R  inhibitors w as also  
included 14 After 33 PC R  cycles, TRAP products w ere detected using a native 15% 
polyacrylam ide gel and silver staining. W e scored a sam ple as telom erase positive w hen  the 
telom erase-specific 6-bp D N A  ladder w as observed. Presence and intensity o f  the ladders 
(com paring the protein input concentrations) determined w hether a sam ple w as classified  as 
negative (-), uncertain (+ /-) or positive (+, ++, or +++).
Quantification  o /h T E R T  mRNA
Total R N A  w as isolated  from the urine and bladder w ash ing cell pellets using Trizol (L ife  
T echnologies, Breda, The N etherlands) and 2 .0  ^g o f  poly[A ] R N A  as precipitation carrier. 
A fter com pleting the manufacturer’s protocol, R N A  w as d issolved  in 20  ^l o f  R N ase-free  
water (L ife T echnologies). H a lf o f  the R N A  (10 ^l) w as denatured at 90°C  for 5 m inutes and 
cooled  im m ediately on ice. R everse transcriptase m ix (10 ^l) w as added containing: RT
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buffer, 25 U  MultiScribe RT, 8 U  RNase Inhibitor, 2.5 ^M dN6, 500 ^M deoxynucleotides, 
and 5.5 ^M M gCl2 (all components from Perkin Elmer Biosystem s, Foster City, CA, USA). 
After annealing o f  the hexanucleotides for 10 minutes at 25°C, cD N A  synthesis was 
performed for 30 minutes at 48°C followed by an enzyme inactivation step at 95°C for 5 
minutes. Real-time quantitative PCR reaction parameters and data analysis for 18S rRNA and
15-17hTERT m RNA expression were described previously in detail 15-17.
Results
Suspected tumor lesions, based on results from cystoscopy, were resected transurethrally from 
the bladder o f  42 patients. The presence o f  a tumor could be confirmed by histology in 36 
patients, but not in 6 (Table 1). The second voided urine and a bladder washing were collected  
from all patients before tumor resection. The urine samples were used to compare TRAP and 
hTERT expression measurements as a noninvasive diagnostic tool for the detection o f  
recurrent UCC. The bladder washings were used to investigate the value o f  cytology, TRAP, 
or hTERT expression for the detection o f  potential aggressive tumors as a supplement to 
cystoscopy. In addition, the bladder washings o f  14 catheterized control patients without 
malignant disease were analyzed to determine specificity.
Urvne
Telomerase activity could be detected with TRAP in 10 o f 35 (29%) urine samples o f  patients 
with confirmed UCC, but not in the 6 patients without evidence o f  tumor in the bladder (Table 
1). hTERT m RNA expression had similar sensitivity and could be detected in 8 o f  33 (24%) 
o f  the urines o f  patients with confirmed UCC. A lso the specificity was similar to TRAP; none 
o f  the 6 patients without tumor evidence contained hTERT m RNA in the urine. Sensitivity o f  
both methods was highest for high grade tumors (III) with invasion o f  the lamina propria 
(Table 1).
Bladder washings
In the cytology reports, malignancy was confirmed by the presence o f  low  or high grade cells 
in 13 o f  34 (38%) bladder wash samples o f  patients with UCC, and suspected in 11 o f  34 
(32%)(Table 1). Especially high grade (III) tumors, including CIS, were correctly identified 
with cytology; 8 o f  13 (62%) washes from patients with high grade tumors contained high 
grade cells. In three o f  the six patients without evidence o f  tumor in the biopsy specimen, 
cells o f  low  grade malignancy were observed or suspected in the bladder washings.
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Table 1. Com parison o f  methods fo r  the diagnosis o f  bladder cancer in urine and bladder 






1 No evidence of tumor - - Suspicion - -
2 No evidence of tumor - - - - -
3 No evidence of tumor - - - - -
4 No evidence of tumor - - - +/- -
5 No evidence of tumor - - Low grade - -
6 No evidence of tumor - - Low grade + 1.10
7 TaGI - - - - -
8 TaGI - - Suspicion + 2.81
9 TaGI - N.A. - - -
10 TaGI - - Suspicion - -
11 TaGI - - - - -
12 TaGI N.A. N.A. Suspicion - -
13 TaGI - - - - -
14 TaGII - - - - -
15 TaGII ++ 0.09 - +++ 1.94
16 TaGII + - - + -
17 TaGII - - Low grade - -
18 TaGII (multiple tumors) - - Suspicion - -
19 TaGII - - Low grade ++ 0.50
20 TaGII - 0.65 N.A. ++ 0.42
21 TaGII + - High grade ++ 3.33
22 TaGII - - Suspicion - -
23 TaGII - - - - -
24 TaGII - - Suspicion - -
25 TaGII - - - - -
26 TaGII ++ - High grade +++ 23.27
27 TaGII - - Low grade +++ 1.91
28 TaGIII - - Suspicion - -
29 TaGIII (multiple tumors) - - Suspicion ++ 0.55
30 T1GII - - - - -
31 T1GII - - N.A. +++ 6.59
32 T1GIII - - High grade ++ 4.66
33 T1GIII +++ N.A. High grade +++ 34.51
34 T1GIII - - Suspicion +/- -
35 T1GIII + CIS ++ 2.48 High grade +++ 14.68
36 T1GIII + CIS +++ 1.01 High grade +++ 21.01
37 T1GIII + CIS + 8.09 High grade ++ 42.02
38 T1GIII + CIS ++ 0.79 High grade + 29.75
39 T1GIII + CIS - - Suspicion - -
40 T2GIII + 2.55 Suspicion ++ 3.10
41 T2GIII - 0.62 High grade ++ 13.19
42 T2GIII - - High grade +/++ 25.23
43-56 Nonmalignant Controls N.A. N.A. N.A. - -
a Tumors were classified using TNM classification 18 and WHO grading system 19 
b Normalized hTERT = 100 x (hTERT/rRNA) l5-17.
- no telomerase activity, hTERT mRNA, or malignant cells detectable.
N.A. Not Available 
c Carcinoma in situ
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Telom erase activity (TR A P) w as detected in 20 o f  36 (56% ) o f  the w ash sam ples o f  
patients w ith  confirm ed carcinom a (Table 1). H ow ever, in tw o w ash ings o f  patients w ithout 
tumor evidence, a 6-bp ladder w as seen (in duplicate experim ents) using the m axim um  
amount o f  protein (6 ^g) in the assay. TRAP could detect all patients w ith  CIS, except for one  
(case 39), but could not discrim inate them  from lo w  grade tumors by the intensity o f  the 6-bp  
ladder. N o  telom erase activity w as observed in the 14 bladder w ash ings from nonm alignant 
specificity  controls.
Sensitivity o f  hTERT m R N A  quantification w as similar to TRAP results; 18 o f  36  
(50% ) w ash sam ples from patients w ith  tumor contained hTERT m R N A . In one bladder 
w ashing o f  a patient w ithout evidence o f  tumor (case 6), hTERT m R N A  w as found. B ecause  
this sam ple w as also positive for both TRAP and cytology, the patient m ay have been  
m isclassified  i f  the tumor w as m issed  during transurethral resection or w as not correctly  
classified  at the pathology department. N on e o f  the nonm alignant controls contained hTERT  
m R N A  in the w ashings. In contrast to TRAP, hTERT expression could discrim inate high  
grade tumors from lo w  grade tumors by bladder w ash analysis. B y  u se o f  a hTERT cu toff  
level o f  6 .80, as w as determined in U C C  to discrim inate high grade tumors from lo w  and 
m edium  grade tumors 16, only 1 o f  23 (4% ) w ashings o f  patients w ith  low  and m edium  grade 
tumors had hTERT expression above this level, whereas 7 o f  13 (54% ) o f  the w ashings o f  
patients w ith  high grade tumors had hTERT expression above 6 .80
Discussion
C ystoscopy is the m ost sensitive m ethod for the detection o f  recurrent bladder cancer. It is 
often aided by urine or w ash cyto logy  to detect (the occurrence of) potentially aggressive non- 
papillary carcinom a in situ  adjacent to the tumor or small high grade invasive tumors 
frequently m issed  w ith cystoscopy 6,7.
Urine cyto logy  as a stand-alone m onitoring tool is noninvasive and less expensive than
3,5,7cystoscopy. H ow ever, sensitivity is poor, especially  for lo w  grade tumors . The lim itations 
o f  cyto logy  as a tool for primary diagnosis and m onitoring o f  patients after transurethral 
rem oval o f  U C C  resulted in the developm ent o f  n ew  urine-bound tests for early tumor 
detection 5. In a recent study, the sensitivity and specificity  o f  urine cytology, B T A  stat, 
N M P22, fibrin/fibrinogen degradation products, telom erase activity, chem ilum inescent
hem oglobin, and the hem oglobin  dipstick w ere com pared prospectively for the detection o f
20primary bladder cancer 20. A lthough telom erase had the best perform ance w ith a sensitivity  
and specificity  o f  70%  and 99%, respectively, it did not equal the sensitivity o f  cystoscopy.
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In our study, the conclusion  w as identical; neither TRAP (29% ), nor real-tim e hTERT-
PC R  (24% ) m easurem ents in urine w ere sensitive enough to replace cystoscopy. D albagni et
21al. found similar sensitivity for the TRAP (35% ), also using the urine o f  patients w ith  
recurrent bladder carcinom as. H ow ever, others have reported both higher and low er
9 11 22sensitivities for the detection o f  telom erase activity in vo ided  urine . The sensitivity  
differences in these studies com pared to our study m ay represent either patient group selection  
(primary versus recurrent U C C ) or inter-laboratory variations o f  the TRAP. To im prove the
23sensitivity in urine, the first m orning urine instead o f  the second urine m ay be used  . A lso  
the use o f  bladder w ashings for tumor diagnostics w as m ore sensitive than urine in our study, 
how ever still not enough to replace cystoscopy. M oreover, w ash ings m ust be collected  by  
catheterization, a procedure equally invasive as cystoscopy.
To supplem ent cystoscopy, for the identification o f  potentially aggressive tumors in 
bladder w ashings, the TRAP w as very sensitive but could not discrim inate betw een lo w  and 
high grade tumors. This reflects m ost reports for telom erase activity m easurem ent in bladder 
tumors, w here no correlation w as found w ith grade or stage (as prognostic parameters) using  
the TRAP assay 9,10,24,25 Interestingly, in a recent study in W ilm s’ tumors, not telom erase  
activity but hTERT m R N A  expression w as found to correlate w ith tumor recurrence as a 
prognostic parameter 26. This disparity in findings w as attributed to lim itations o f  the TRAP  
assay, for instance the lack o f  a control for R N A  tem plate degradation 13,14,26. In contrast, the 
real-tim e hTERT assay contains such an endogenous control (18S  rR N A) that norm alizes for 
various parameters affecting the assay 15. Indeed, in a previous study using bladder tissues o f  
different grades, w e  could determine a hTERT cu to ff level o f  6 .80 to distinguish betw een  
grade III and grade I and II tumors 16. This discrim ination is important clin ically, because  
grade III superficial tumors have a high progression rate; 50% for T1 and 25%  for Ta tumors 
27,28. U sin g  this cu toff level o f  6 .80  in the present study, w e  could identify 7 o f  13 (54% ) high  
grade tumors including 4 o f  5 patients w ith  carcinom a in situ  in the w ashings. A lso  a 
superficial m edium -grade tumor (case 26 ) had high hTERT expression. C lose fo llow -up  o f  all 
patients w ill reveal w hether hTERT quantification in the w ashings correctly predicted  
progression in these 8 patients w ith  hTERT expression  >6 .80 , but not in patients w ith  low er  
or absent expression. This w ould  also reveal w hether hTERT expression is directly related to 
progression, independent o f  grade.
In this study, no d ifferences w ere observed betw een  hTERT m R N A  quantification and 
cyto logy  for the identification o f  high grade tumors in bladder w ashings. H ow ever, hTERT  
quantification m ay specifica lly  identify those high grade tumors that w ill progress. M oreover,
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the assay is more standardized (by the use o f  a computer), resulting in reduced inter- and 
intra-observer variability compared to cytological examination.
W e conclude that neither telomerase activity nor hTERT expression measurements in 
urine were sensitive enough to replace cystoscopy as a diagnostic tool. However, the 
quantification o f  hTERT expression in bladder washings could identify recurrent tumors with 
high progression risk. Follow-up monitoring will be necessary to substantiate whether hTERT 
quantification can predict tumor progression by use o f  bladder washings as a supplement to 
cystoscopy.
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Solid tumors can shed whole cells or free nucleic acids in body fluids, such as bile, stool, 
sputum, blood, and cerebrospinal fluid. Body fluids (in contrast to biopsies) may be o f  special 
interest for confirmation o f  tumor presence, because they can be obtained with noninvasive or 
minimally invasive techniques. N ext to possibilities for screening and follow-up, body fluids 
may be used in symptomatic patients to detect tumor presence, to demonstrate systemic 
disease, to determine effect o f  therapy, or to supplement other diagnostic techniques.
The increasing fundamental knowledge about the genetic changes that initiate 
malignant transformation and subsequently drive cancer growth and progression, provides a 
variety o f  tumor markers. These new markers can be used in clinical studies to detect tumors 
based on the presence o f  aberrant D N A  or changes in RNA expression. However, in body 
fluids, conventional detection techniques are usually not sensitive enough to analyze minute 
amounts o f  nucleic acids. The development o f  sensitive and reproducible D N A /R N A  isolation 
techniques and powerful amplification methods has led to increasing molecular research in 
body fluids. A  starting point was the study o f  David Sidransky and colleagues (Science  
1991;252:706-9), who applied these new techniques to body fluids and showed that tumor- 
specific D N A  mutations could be detected in the urine o f  patients with bladder cancer. This 
new fascinating field o f  clinical research is o f  great interest for clinical chemistry and was the 
motivation for the studies described in this thesis.
Detection of tumor DNA in body fluids
Good test-characteristics o f  a D N A  isolation procedure are essential for tumor-diagnostics in 
body fluids. Chapter 2 describes a new system, real-time quantitative PCR (ABI Prism 7700  
Sequence Detection System, Perkin-Elmer Applied Biosystem s), to compare isolation 
methods. First, the system was validated as a quality-control system. Subsequently, it was 
used to compare characteristics o f  different D N A  isolation methods. Plasma was chosen in 
this study as model for a body fluid. Within-run and between-day differences o f  the PCR  
system were small. After this validation, a D N A  salting-out procedure (PureGene, Gentra 
systems) was identified as most sensitive and repeatable o f  four tested methods. This method 
(followed by an additional column purification) was adopted to isolate D N A  from all body 
fluids (chapters 3 to 5).
Chapter 3 describes the detection o f  free circulating tumor D N A  in serum o f  patients 
with colorectal carcinomas and metastatic disease. In 6 o f  7 patients with a K-ras oncogene
Summary and General Discussion
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mutation in the tumor, the presence of identical mutations could be confirmed in serum. This 
study shows that circulating tumor DNA is frequently present in patients with systemic 
colorectal disease and poor prognosis, and corroborates other studies in patients with 
metastatic tumors. It should be further investigated whether tumor DNA analysis in serum can 
identify patients that have clinically localized disease at presentation but will develop 
systemic disease in the follow-up.
Chapter 4 describes the detection of K-ras mutations in the bile of patients with 
metastatic liver disease from primary colorectal carcinomas. Five patients were selected with 
extensive disease in the liver containing a K-ras mutation. In spite of the large tumor mass 
and the validation of techniques for DNA isolation and mutation detection, a K-ras mutation 
could be detected in bile of only one patient. From this pilot study it was concluded that 
(extensive) liver metastases do not frequently shed tumor cells or free DNA into bile. 
Therefore, localization of metastases in the liver by analysis of bile will not be feasible.
Metastases in the leptomeninges from primary lung tumors could be detected in the 
cerebrospinal fluid of two patients. (Chapter 5). The presence of these metastases was 
demonstrated with molecular techniques, i.e. K-ras mutation analysis, preceding cytological 
confirmation, currently the golden standard. This is important clinically, because early 
detection of metastases increases the effect of palliative treatment.
Quantification of tumor RNA in body fluids
Chapter 6 describes the development of a method for the accurate quantification of hTERT 
mRNA, coding for the catalytic subunit of the enzyme telomerase which is needed for the 
immortalization of neoplasms. Because the expression of hTERT is normalized to the 
expression of ribosomal RNA (18S rRNA), variations between samples in RNA amounts, 
RNA quality, and RT efficiency are corrected. Therefore, gene expression differences 
between samples can be compared directly. hTERT expression was measured in different cell 
lines, primary cell cultures, and healthy tissues. A distinct difference in hTERT expression 
was observed between cell lines and healthy tissues. Quantification of hTERT expression in 
tumors and body fluids might be a promising marker for cancer detection.
Chapter 7 describes how this hypothesis was tested. Five different types of tissues 
associated with body fluids were selected; pancreas, lung, colon, esophagus, and urine 
bladder. Healthy and tumor tissues were tested for amounts of hTERT mRNA. All tumor 
tissues expressed hTERT, whereas all healthy tissues (except for colon) had lower or no 
hTERT expression. Subsequently, bladder tumors were selected for a more extensive analysis.
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Chapter 8 describes the measurement o f  hTERT in 35 bladder tumors and 6 healthy 
bladders. Sensitivity and specificity for the detection o f  tumor were both 100%. Moreover, a 
correlation was found with prognosis, defined by stage and grade o f  the tumor. After 
calculation o f  hTERT cutoff values, real-time quantitative hTERT measurement in tumors 
could discriminate between low  and high grade tumors, and between superficial and invasive 
tumors. These results indicated that quantitative measurement o f  hTERT mRNA in urine or 
bladder washings may not only detect bladder tumors, but may also identify tumors with poor 
prognosis.
Chapter 9 describes quantification o f  hTERT m RNA in urine and bladder washings 
o f  patients with recurrent bladder cancers. N ext to hTERT mRNA, also telomerase activity 
was determined in the urine and washing samples. Sensitivity for the detection o f  recurrences 
in urine was low  for both hTERT and telomerase. However, the quantification o f hTERT 
expression in bladder washings could identify recurrent tumors with high progression risk 
when a hTERT cutoff value was used (as described in chapter 8). Follow-up monitoring will 
be necessary to substantiate whether hTERT quantification can predict tumor progression as 
an independent marker in bladder washings to supplement cystoscopy.
General discussion
The results o f  the studies described in this thesis corroborate the interesting applications o f  
molecular tumor-diagnostics in body fluids. In agreement with recent literature reports, our 
results confirm that aggressive and metastatic tumors frequently shed cells or free D N A  in 
body fluids, whereas small non-invasive tumors can be detected less frequently. Therefore, 
detection o f  molecular tumor markers in body fluids offers good prospects for diagnosis o f  
systemic disease or the (imminent) progression o f  a tumor, both resulting in poor prognosis. 
However, molecular diagnostics in body fluids is still in it’s infancy, and many criteria have 
to be fulfilled before introduction into the clinic can be realized.
One aspect to consider is the extreme sensitivity o f  the PCR technique. Although this 
sensitivity is necessary to detect minute amounts o f  nucleic acids in body fluids, it inherently 
produces false-positive results i f  precautions to prevent sample contamination are not taken. 
PCR amplicons from previous experiments are the main source o f  contamination and this risk 
can be reduced significantly when PCR products are analyzed without opening the reaction 
tube after PCR, such as by fluorescent monitoring o f  amplicon formation using real-time PCR  
systems.
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Another aspect is the specificity o f  molecular RNA markers. In contrast to DN A  
mutations in oncogenes or tumor suppressor genes that are usually tumor-specific, current 
R N A expression markers are tumor-associated but not tumor-specific. Up to now, no single 
gene has been identified that is solely expressed in tumors, except for chimeric genes due to 
chromosome translocations. M ost tumor-associated genes are up or down-regulated in tumor 
tissues compared to healthy tissues, and cutoff values must be determined with real-time 
quantitative PCR to differentiate between healthy and tumor cells. However, in a high 
background o f  normal cells with low  expression, few  tumor cells with high expression can not 
be discriminated. If possible, contaminating cells must be removed. For instance, hTERT 
m RNA is expressed in subsets o f  lymphocytes. Since body fluids are often contaminated with 
blood, selection o f  tissue cells (or removal o f  blood) is necessary to prevent erroneous 
interpretation o f  results.
Finally, inter- and intra-laboratory standardization is very complicated because o f  the 
many variables involved in the pre-analytical, analytical, and post-analytical phases. In the 
pre-analytical phase, timing o f  sample collection may be important; for example, first or 
second voided urine. A lso the period between collection and storage/analysis o f  the samples 
may influence results. To facilitate standardized processing o f  samples, hence reproducibility, 
a nuclease inhibitor can be developed and added to body fluids directly after collection. In the 
analytical phase, D N A/RN A degradation, isolation efficiency, or inefficient removal o f  
inhibitors can be normalized by co-amplification o f  an endogenous target (DNA or RNA) 
next to the gene o f  interest. Moreover, PCR amplification can be standardized, for instance by 
development o f  ready-made PCR master mixes. The development o f  universal calibrators 
enables the comparison o f  quantitative gene-expression data o f  different laboratories. In the 
post-analytical phase, the introduction o f  computer programs that automatically analyze data 
will reduce inter-observer variability in visual interpretation o f  data.
Generally, the initial studies o f  molecular tumor-detection in body fluids are promising 
and stimulate further research. The novel developments in chip technology will facilitate 
molecular detection and will simultaneously provide new tumor markers. Reliable nucleic 
acid isolation protocols together with methods for the detection o f  D N A  mutations against a 
high background o f  normal D N A  should be selected. Inevitably, those methods that are “user 
friendly” and amenable to automation will ultimately becom e the ones that will be o f  clinical 
use. In the coming years, it is likely that molecular tumor-detection in body fluids will 
becom e an important tool for clinicians.
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Samenvatting
M aligne processen in het lichaam kunnen hele cellen o f  vrije nucleinezuren (D N A  en RNA) 
uitscheiden in lichaam svloeistoffen zoals urine, gal, ontlasting, speeksel, bloed en 
hersenvloeistof. Lichaamsvloeistoffen, in tegenstelling tot biopten, zijn met name interessant 
voor de bevestiging van de aanwezigheid van een tumor, omdat ze op een niet- o f  weinig  
patiënt-belastende manier kunnen worden verkregen. Naast mogelijkheden voor screening en 
nabehandeling kunnen lichaam svloeistoffen wellicht ook worden gebruikt bij symptomatische 
patiënten voor het aantonen van een tumor, voor het opsporen o f  bevestigen van de 
aanwezigheid van uitzaaiingen, voor de bepaling van de effectiviteit van therapie o f  als 
aanvulling op andere diagnostische technieken (b.v. cytologie).
D e groeiende fundamentele kennis over de genetische veranderingen die ten grondslag 
liggen aan het ontstaan en de progressie van maligne processen vormt een bron van 
moleculaire merkers. D eze merkers kunnen worden gebruikt in klinische studies om tumoren 
aan te tonen op basis van hun afwijkende D N A  o f  veranderde R N A expressie. Echter in 
lichaam svloeistoffen is de hoeveelheid van een tumor afkomstige nucleïnezuren meestal zeer 
gering en conventionele technieken zijn niet gevoelig genoeg om deze minieme hoeveelheden 
aan te tonen. D e ontwikkeling van sensitieve en reproduceerbare D N A - en RNA  
isolatietechnieken parallel aan de ontwikkeling van D N A  vermenigvuldigingsmethoden heeft 
het afgelopen decennium geleid tot een explosieve groei van het onderzoek naar de 
mogelijkheden van moleculaire tumordiagnostiek in lichaamsvloeistoffen. Een startpunt was 
de studie van David Sidransky (Science 1991;252:706-9) die deze nieuwe technieken toepaste 
op lichaam svloeistoffen en liet zien dat bij patiënten met een blaastumor, D N A  mutaties 
afkomstig van de tumor konden worden aangetoond in de urine. D it nieuwe fascinerende 
vakgebied met vele mogelijke toepassingen voor tumordiagnostiek is van grote interesse voor 
de klinische chemie en daarom de aanleiding voor de vraagstellingen en resulterende studies 
beschreven in dit proefschrift.
Aantonen van tumor DNA in lichaamsvloeistoffen
Goede testkarakteristieken van een D N A  isolatiemethode zijn van essentieel belang voor 
diagnostiek in lichaamsvloeistoffen. In hoofdstuk 2 staat beschreven hoe een nieuw systeem  
voor kwantitatieve PCR eerst is gevalideerd en vervolgens is gebruikt als kwaliteitscontrole- 
systeem voor het vergelijken van isolatie-efficiëntie en reproduceerbaarheid van verschillende 
D N A  isolatiemethoden. Plasma werd in deze studie gekozen als model voor een
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lichaam svloeistof. H et systeem  b leek  zeer reproduceerbaar, zow el binnen een m eting als 
tussen dagen. N a  validering van het systeem  werd van de v ier onderzochte m ethoden de 
D N A -uitzoutingsm ethode als m eest g ev o e lig  en reproduceerbaar getest voor D N A  isolatie uit 
plasma. D eze  m ethode, al o f  niet in com binatie m et een extra (kolom )zuiveringsstap, is 
gebruikt voor alle D N A  isolaties uit lichaam svloeistoffen  beschreven in de hoofdstukken 3 tot 
en m et 5.
In hoofdstuk 3 werd de aanw ezigheid  van vrij circulerend tumor D N A  in het serum  
van patiënten m et u itgezaaide darmtumoren bestudeerd. In 6 van de 7 patiënten m et een K -ras  
oncogenm utatie in de darmtumor, kon een identieke mutatie in het serum worden aangetoond. 
D eze  studie liet in navolging van studies m et andere tumoren zien  dat circulerend tumor D N A  
frequent aanw ezig w as in patiënten m et system ische ziekte en dus slechte prognose. Verder 
onderzoek m oet u itw ijzen  o f  m iddels serum analyse patiënten kunnen w orden geïdentificeerd  
m et een darmtumor zonder m etastasen, die tijdens nabehandeling uitzaaiingen ontwikkelen.
In hoofdstuk 4 werd bestudeerd o f  K -ras m utaties konden worden aangetoond in de 
gal van patiënten m et uitzaaiingen in de lever, afkom stig van een darmtumor. V ijf  patiënten  
werden geselecteerd  m et een grote tum orm assa in de lever en een K -ras mutatie. Ondanks de 
grote tum orm assa en de validering van de gebruikte technieken voor D N A - isolatie en  
m utatiedetectie, kon slechts in één van de v ij f  patiënten een K -ras mutatie w orden aangetoond  
in de gal. U it deze inventariserende studie kon worden geconcludeerd dat (grote) 
leverm etastasen niet frequent tum orcellen o f  vrij tum or-D N A  uitscheiden in de gal. H et zal 
daarom het niet m ogelijk  zijn m iddels gal-analyse uitzaaiingen te lokaliseren in de lever.
W el w as het m ogelijk  uitzaaiingen naar de hersenvliezen  (vanuit een longtum or) aan 
te tonen in de hersenvloeisto f van 2 patiënten (H o o fd stu k  5). D e  aanw ezigheid van  
m etastasen in de hersenvliezen  van deze patiënten kon eerder worden aangetoond door K -ras  
m utatie-analyse dan m et behulp van cytologie, de huidige gouden standaard. D it is van belang  
omdat vroege detectie van uitzaaiingen het effect van (palliatieve) behandeling vergroot.
Kwantificeren van tumor RNA in lichaamsvloeistoffen
Hoofdstuk 6 beschrijft de ontw ikkeling van een m ethode voor de nauw keurige kw antificering  
van hTERT m R N A , dat codeert voor de katalytische subunit van het enzym  telom erase. 
D oordat de expressie van het hTERT gen in deze procedure genorm aliseerd wordt door de 
expressie van ribosom aal R N A  (18S  rRNA), worden variaties tussen m onsters in R N A  
hoeveelheden, R N A  kw aliteit en reverse-transcriptase efficiën ties gecorrigeerd. 
E xpressieverschillen  tussen m onsters kunnen daardoor direct m et elkaar worden vergeleken.
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Verschillende tumorcellijnen, primaire kweken en normale w eefsels werden getest voor de 
expressie van hTERT. Er was een duidelijk verschil in expressie tussen tumorcellijnen en 
normale weefsels. M eting van hTERT genexpressie in tumoren en lichaam svloeistoffen zou  
daarom een goede tumormerker kunnen kunnen opleveren voor de diagnostiek.
In hoofdstuk 7 staat beschreven hoe deze hypothese werd getest. V ijf organen werden 
geselecteerd met een nauwe relatie tot een lichaamsvloeistof; alvleesklier, long, darm, 
slokdarm en blaas. Van deze organen werden zowel gezonde- als tumorweefsels getest op de 
aanwezigheid van hert mRNA. A lle tumorweefsels brachten hTERT tot expressie. Behalve 
voor darmweefsel hadden alle gezonde w eefsels lagere hTERT expressie dan de bij dat 
orgaan behorende tumoren. Blaastumoren werden geselecteerd voor een meer uitgebreide 
analyse.
In hoofdstuk 8 worden de resultaten beschreven van de hTERT expressiemeting in 35 
blaastumoren en 6 normale blaasweefsels. Naast een 100% gevoeligheid en specificiteit voor 
de detectie van een carcinoom werd tevens een correlatie gevonden met prognose, 
gedefinieerd door stadium en graad van de tumor. Door vervolgens verschillende hTERT 
grenswaarden te berekenen was de kwantitatieve hTERT m RNA meting in staat onderscheid 
te maken tussen laag- en hooggradige tumoren, maar ook tussen oppervlakkige- en invasieve  
blaastumoren. D eze resultaten wezen erop dat hTERT expressiemeting naast waarde als 
diagnostische merker ook m ogelijk bruikbaar zou kunnen zijn voor bepaling van prognose in 
urine o f  blaaswassingen.
In hoofdstuk 9 staan de resultaten beschreven van kwantitatieve hTERT metingen in 
urine en blaaswassingen van patiënten met terugkerende blaastumoren. D e resultaten werden 
vergeleken met activiteitsmetingen van het enzym telomerase. D e gevoeligheid voor 
(vroeg)diagnostiek van blaastumoren in urine was laag voor zowel de activiteits- als de 
hTERT meting. Echter, in blaaswassingen bleek bepaling van hTERT expressie, in 
tegenstelling tot telomerase metingen, geschikt om potentieel agressieve blaastumoren te 
herkennen door gebruik te maken van hTERT grenswaarden als beschreven in hoofdstuk 8 . 
Vervolgstudies zijn nodig om aan te tonen o f  kwantificering van hTERT m RNA kan worden 
gebruikt als onafhankelijke tumormarker in blaaswassingen om tumorprogressie te 
voorspellen.
D e studies die in dit proefschrift zijn beschreven bevestigen de interessante mogelijkheden  
voor de moleculaire diagnostiek van tumoren in lichaamsvloeistoffen. D eze resultaten zijn in 
overeenstemming met bevindingen van andere onderzoeksgroepen en lijken er voornamelijk
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op te wijzen dat alleen (potentieel) agressieve tumoren frequent cellen en D N A  uitstoten in 
lichaamsvloeistoffen, terwijl kleine niet-invasieve tumoren minder frequent kunnen worden 
aangetoond. Daarom biedt het gebruik van moleculaire markers goede perspectieven voor het 
aantonen van uitzaaiingen o f  (toekomstige) progressie van een tumor, resulterend in een 
slechte prognose. Echter de moleculaire tumordiagnostiek in lichaam svloeistoffen staat nog in 
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